

WEST Search History

DATE: Thursday, September 09, 2004

| Hide? | Set Name | Query | Hit Count |
|--------------------------|---|---------------------|-----------|
| | <i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i> | | |
| <input type="checkbox"/> | L19 | L15 AND AScr | 27 |
| <input type="checkbox"/> | L18 | L17 AND AScr | 1 |
| <input type="checkbox"/> | L17 | L16 AND PrPSc | 95 |
| <input type="checkbox"/> | L16 | L15 AND PrP | 581 |
| <input type="checkbox"/> | L15 | prion | 4411 |
| <input type="checkbox"/> | L14 | prion | 4411 |
| <input type="checkbox"/> | L13 | L12 AND PrPSc | 9 |
| <input type="checkbox"/> | L12 | L11 AND PrP | 40 |
| <input type="checkbox"/> | L11 | L10 AND prion | 273 |
| <input type="checkbox"/> | L10 | 514/2,4,12.CCLS. | 12236 |
| <input type="checkbox"/> | L9 | L8 AND PrPSc | 3 |
| <input type="checkbox"/> | L8 | L7 AND PrP | 20 |
| <input type="checkbox"/> | L7 | L6 AND prion | 60 |
| <input type="checkbox"/> | L6 | 424/185.1.CCLS. | 1735 |
| <input type="checkbox"/> | L5 | Schenk.IN. | 2901 |
| <input type="checkbox"/> | L4 | Schenk-D-B.IN. | 17 |
| <input type="checkbox"/> | L3 | Schenk-D.IN. | 7 |
| <input type="checkbox"/> | L2 | Schenk-Dale.IN. | 3 |
| <input type="checkbox"/> | L1 | (Schenk-Dale-B.IN.) | 43 |

END OF SEARCH HISTORY

Hit List

| | | | | | |
|-------|---------------------|-------|----------|-----------|---------------|
| Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS |
|-------|---------------------|-------|----------|-----------|---------------|

Search Results - Record(s) 1 through 27 of 27 returned.

☐ 1. Document ID: US 20040147531 A1

Using default format because multiple data bases are involved.

L19: Entry 1 of 27

File: PGPB

Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040147531

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040147531 A1

TITLE: Amidine derivatives for treating amyloidosis

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|----------------------|---------------------|-------|---------|---------|
| Chalifour, Robert J. | Ile Bizard | | CA | |
| Kong, Xianqi | Pierrefonds | | CA | |
| Wu, Xinfu | Dollard-des-Ormeaux | | CA | |
| Lu, Wenshuo | LaSalle | | CA | |

US-CL-CURRENT: [514/256](#); [514/397](#), [514/636](#)

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|----------|

☐ 2. Document ID: US 20040138178 A1

L19: Entry 2 of 27

File: PGPB

Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138178

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040138178 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|------------------------|-------------|-------|---------|---------|
| Szarek, Walter A. | Kingston | | CA | |
| Kong, Xianqi | Pierrefonds | | CA | |
| Thatcher, Gregory R.J. | Kingston | | CA | |
| Gorine, Boris | Edmonton | | CA | |

US-CL-CURRENT: [514/79](#); [514/114](#), [514/141](#)

ABSTRACT:

h e b b g e e e f e b ef b e

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 3. Document ID: US 20040048279 A1

L19: Entry 3 of 27

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048279

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040048279 A1

TITLE: Method for detecting methylation states for a toxicological diagnostic

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|------------------------|------------|-------|---------|---------|
| Olek, Alexander | Berlin | | DE | |
| Piepenbrock, Christian | Berlin | | DE | |
| Berlin, Kurt | Stahnsdorf | | DE | |

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention concerns a method for toxicological diagnosis. A DNA sample is taken from an organism or a cell culture, which has previously been subjected to a specific substance that is to be investigated for its toxicological effect. The DNA contained in this sample is chemically pretreated and the base sequence of a part of the modified DNA is determined. A methylation state characteristic for the sample or a characteristic methylation pattern is concluded from this. The effect of a substance on the organism or the cell culture is concluded by comparison with data of the methylation states of other samples and/or compared with other substances from a toxicological point of view.

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 4. Document ID: US 20040006092 A1

L19: Entry 4 of 27

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040006092

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040006092 A1

TITLE: Amidine derivatives for treating amyloidosis

h e b b g e e e f e b e f b e

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|----------------------|---------------------|-------|---------|---------|
| Chalifour, Robert J. | Ile Bizard | | CA | |
| Kong, Xianqi | Dollard-des-Ormeaux | | CA | |
| Wu, Xinfu | Dollard-des-Ormeaux | | CA | |
| Lu, Wenshuo | Montreal | | CA | |

US-CL-CURRENT: 514/256; 514/397, 514/632

ABSTRACT:

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWOC | Draw. Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|------------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|------------|

☐ 5. Document ID: US 20030236392 A1

L19: Entry 5 of 27

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030236392

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030236392 A1

TITLE: Novel full length cDNA

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|--------------------|---------|-------|---------|---------|
| Isogai, Takao | Ibaraki | | JP | |
| Sugiyama, Tomoyasu | Tokyo | | JP | |
| Otsuki, Tetsuji | Chiba | | JP | |
| Wakamatsu, Ai | Chiba | | JP | |
| Sato, Hiroyuki | Osaka | | JP | |
| Ishii, Shizuko | Chiba | | JP | |
| Yamamoto, Jun-ichi | Chiba | | JP | |
| Isono, Yuuko | Chiba | | JP | |
| Hio, Yuri | Chiba | | JP | |
| Otsuka, Kaoru | Saitama | | JP | |
| Nagai, Keiichi | Tokyo | | JP | |
| Irie, Ryotaro | Chiba | | JP | |
| Tamechika, Ichiro | Osaka | | JP | |
| Seki, Naohiko | Chiba | | JP | |
| Yoshikawa, Tsutomu | Chiba | | JP | |
| Otsuka, Motoyuki | Tokyo | | JP | |

h e b b g e e e f e b ef b e

| | | |
|------------------|-------|----|
| Nagahari, Kenji | Tokyo | JP |
| Masuhō, Yasuhiko | Tokyo | JP |

US-CL-CURRENT: 536/23.1; 435/183, 435/325, 435/6, 435/69.1, 530/350, 702/19

ABSTRACT:

Novel full-length cDNAs are provided.

1970 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWOC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|

☐ 6. Document ID: US 20030232758 A1

L19: Entry 6 of 27

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232758
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232758 A1

TITLE: Immunological methods and compositions for the treatment of Alzheimer's disease

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

| | | | | |
|-----------------------------|---------|-------|---------|---------|
| NAME | CITY | STATE | COUNTRY | RULE-47 |
| St. George-Hyslop, Peter H. | Toronto | | CA | |
| McLaurin, JoAnne | Toronto | | CA | |

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/324, 536/23.1

ABSTRACT:

The present invention relates to immunogenic compositions and peptides comprising residues 4-10 (FRHDSGY) of the amyloid peptide Abeta.sub.42. The invention further relates to antibodies that bind to the Abeta.sub.(4-10) antigenic determinant. The invention provides methods for treating Alzheimer's disease and for reducing the amyloid load in Alzheimers patients. The invention also relates to methods for designing small molecule inhibitors of amyloid deposition.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWOC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|

☐ 7. Document ID: US 20030185808 A1

L19: Entry 7 of 27

File: PGPB

Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030185808

h e b b g e e e f e b e f b e

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030185808 A1

TITLE: Prostate cell lines

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|----------------|--------|-------|---------|---------|
| Thraves, Peter | London | | GB | |
| Sutton, Andrew | London | | GB | |

US-CL-CURRENT: 424/93.21; 424/85.2, 435/366, 514/44

ABSTRACT:

An increasingly aged population and better diagnosis has lead to an apparent increase in the prevalence of prostate cancer in men. There is an acute need to better understand the progression of this disease from its locally confined site of initiation to the end stage widely metastatic disease with attendant morbidity and mortality. It has historically been difficult to raise and maintain immortalised prostate cell lines in culture. We have derived a cell line selected from the group consisting of clones ONYCAP 1 and ONYCAP23. The cell lines are characterised as being prostate epithelial in origin.

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KIMC | Draw. Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|------------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|------------|

☐ 8. Document ID: US 20030108595 A1

L19: Entry 8 of 27

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108595

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108595 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|--------------------|----------|-------|---------|---------|
| Kisilevsky, Robert | Kingston | | CA | |
| Szarek, Walter | Kingston | | CA | |
| Weaver, Donald | Kingston | | CA | |

US-CL-CURRENT: 424/450; 514/12, 514/23, 514/378, 514/381, 514/460, 514/79

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates

h e b b g e e f e b ef b e

and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 9. Document ID: US 20030027796 A1

L19: Entry 9 of 27

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027796

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027796 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|------------------------|---------------------|-------|---------|---------|
| Szarek, Walter A. | Kingston | | CA | |
| Kong, Xianqi | Dollard-des-Ormeaux | | CA | |
| Thatcher, Gregory R.J. | Kingston | | CA | |
| Gorine, Boris | Edmonton | | CA | |

US-CL-CURRENT: 514/79; 514/114, 514/141

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 10. Document ID: US 20020119926 A1

L19: Entry 10 of 27

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119926

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119926 A1

TITLE: Inhibitors of IAPP fibril formation and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|------|------|-------|---------|---------|
|------|------|-------|---------|---------|

h e b b g e e f e b e f b e

Fraser, Paul

Toronto

CA

US-CL-CURRENT: 514/12; 435/184, 514/14, 514/15, 514/16, 514/17

ABSTRACT:

New antifibrillogenic agents and compositions containing same, methods of using the antifibrillogenic agents and compositions for inhibiting amyloid fibril formation, and effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes.

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 11. Document ID: US 20020115717 A1

L19: Entry 11 of 27

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115717

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020115717 A1

TITLE: Amyloid targeting imaging agents and uses thereof

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|-------------------|---------------------|-------|---------|---------|
| Gervais, Francine | Ile Bizard | | CA | |
| Kong, Xianqi | Dollard-des-Ormeaux | | CA | |
| Chalifour, Robert | Ile Bizard | | CA | |
| Migneault, David | Laval | | CA | |

US-CL-CURRENT: 514/553; 424/1.11

ABSTRACT:

Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|-----------|

☐ 12. Document ID: US 20020094335 A1

L19: Entry 12 of 27

File: PGPB

Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094335

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020094335 A1

h e b b g e e e f e b e f b e

TITLE: Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|-------------------|---------------------|-------|---------|---------|
| Chalifour, Robert | Ile Bizard | | CA | |
| Hebert, Lise | Brossard | | CA | |
| Kong, Xianqi | Dollard-des-Oremaux | | CA | |
| Gervais, Francine | Ile Bizard | | CA | |

US-CL-CURRENT: 424/185.1

ABSTRACT:

The present invention relates to a stereochemically based "non-self" antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring peptides, proteins or immunogens.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|

☐ 13. Document ID: US 20020009730 A1

L19: Entry 13 of 27

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009730

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020009730 A1

TITLE: Human stress array

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---------------------|-----------|-------|---------|---------|
| Chenchik, Alex | Palo Alto | CA | US | |
| Lukashev, Matvey E. | Newton | MA | US | |

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|------|----------|

h e b b g e e e f e b e f b e

☐ 14. Document ID: US 20010048941 A1

L19: Entry 14 of 27

File: PGPB

Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010048941
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010048941 A1

TITLE: Method for treating amyloidosis

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|--------------------|----------|-------|---------|---------|
| Kisilevsky, Robert | Kingston | | CA | |
| Szarek, Walter | Kingston | | CA | |
| Weaver, Donald | Kingston | | CA | |

US-CL-CURRENT: 424/450; 514/2, 514/378, 514/381, 514/460, 514/54

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | FIG | Draw | Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|------|------|
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|------|------|

☐ 15. Document ID: US 20010027186 A1

L19: Entry 15 of 27

File: PGPB

Oct 4, 2001

PGPUB-DOCUMENT-NUMBER: 20010027186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010027186 A1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

PUBLICATION-DATE: October 4, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|-----------------------|---------------------|-------|---------|---------|
| Szarek, Walter A. | Kingston | | CA | |
| Kong, Xianqi | Dollard-des-Ormeaux | | CA | |
| Thatcher, Gregory R.J | Kingston | | CA | |
| Gorine, Boris | Edmonton | | CA | |

US-CL-CURRENT: 514/79; 514/114, 514/129, 514/142

h e b b g e e e f e b ef b e

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|-----------|-------------|--------|-----|----------|

☐ 16. Document ID: US 6632808 B1

L19: Entry 16 of 27

File: USPT

Oct 14, 2003

US-PAT-NO: 6632808

DOCUMENT-IDENTIFIER: US 6632808 B1

TITLE: Inhibitors of amyloid formation

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---------------------|----------|-------|----------|---------|
| Caughey; Winslow S. | Hamilton | MT | | |
| Caughey; Byron | Hamilton | MT | | |

US-CL-CURRENT: 514/185; 514/410, 540/122, 540/145

ABSTRACT:

Methods, compounds and compositions are disclosed for treating amyloidogenic diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.

70 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

| | | | | | | | | | | | | |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|
| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|

☐ 17. Document ID: US 6562836 B1

L19: Entry 17 of 27

File: USPT

May 13, 2003

US-PAT-NO: 6562836

h e b b g e e e f e b e f b e

DOCUMENT-IDENTIFIER: US 6562836 B1

**** See image for Certificate of Correction ****

TITLE: Methods and compounds for inhibiting amyloid deposits

DATE-ISSUED: May 13, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|---------------------|-------|----------|---------|
| Szarek; Walter A. | Kingston | | | CA |
| Weaver; Donald F. | Kingston | | | CA |
| Kong; Xianqi | Dollard-des-Ormeaux | | | CA |
| Gupta; Ajay | Pointe-Claire | | | CA |
| Migneault; David | Laval | | | CA |

US-CL-CURRENT: 514/307; 514/308, 514/311, 514/313, 514/314

ABSTRACT:

Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

172 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 14

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|-----------|

☐ 18. Document ID: US 6440952 B2

L19: Entry 18 of 27

File: USPT

Aug 27, 2002

US-PAT-NO: 6440952

DOCUMENT-IDENTIFIER: US 6440952 B2

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------------|---------------------|-------|----------|---------|
| Szarek; Walter A. | Kingston | | | CA |
| Kong; Xianqi | Dollard-des-Ormeaux | | | CA |
| Thatcher; Gregory R. J. | Kingston | | | CA |
| Gorine; Boris | Edmonton | | | CA |

US-CL-CURRENT: 514/120; 558/110, 558/70

h e b b g e e e f e b e f b e

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | Claims | FIGS | Draw Desc |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|-----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|-----------|

☐ 19. Document ID: US 6355784 B1

L19: Entry 19 of 27

File: USPT

Mar 12, 2002

US-PAT-NO: 6355784

DOCUMENT-IDENTIFIER: US 6355784 B1

**** See image for Certificate of Correction ****

TITLE: Methods and compositions for the manufacture of halogenated anthracyclines with increased antitumor activity, other anthracyclines, halogenated sugars, and glycosyl donors

DATE-ISSUED: March 12, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-----------------------|-----------------|-------|----------|---------|
| Priebe; Waldemar | Houston | TX | 77005 | |
| Krawczyk; Marta | Lexington | KY | 40503 | |
| Skibicki; Piotr | Warsaw 04015 | | | PL |
| Fokt; Izabela | The Woodlands | TX | 77380 | |
| Dziewiszek; Krzysztof | The Woodlands | TX | 77380 | |
| Gryniewicz; Grzegorz | 05-092 Lomianki | | | PL |
| Perez-Soler; Roman | New York | NY | 10016 | |

US-CL-CURRENT: 536/6.4; 536/122, 536/17.2, 536/18.4, 536/18.7, 536/4.1

ABSTRACT:

The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4'- and 6'-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimer's disease is contemplated.

7 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|

☐ 20. Document ID: US 6329356 B1

L19: Entry 20 of 27

File: USPT

Dec 11, 2001

US-PAT-NO: 6329356

DOCUMENT-IDENTIFIER: US 6329356 B1

TITLE: Phosphono-carboxylate compounds for treating amyloidosis

DATE-ISSUED: December 11, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|---------------------|-------|----------|---------|
| Szarek; Walter A. | Kingston | | | CA |
| Kong; Xianqi | Dollard-des-Ormeaux | | | CA |

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

31 Claims, 0 Drawing figures

Exemplary Claim Number: 1

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KMC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|

☐ 21. Document ID: US 5972328 A

L19: Entry 21 of 27

File: USPT

Oct 26, 1999

US-PAT-NO: 5972328

DOCUMENT-IDENTIFIER: US 5972328 A

**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|----------|-------|----------|---------|
| Kisilevsky; Robert | Kingston | | | CA |
| Szarek; Walter | Kingston | | | CA |
| Weaver; Donald | Kingston | | | CA |

US-CL-CURRENT: 424/78.31, 424/423, 424/427, 424/430, 424/434, 424/436, 424/441,

h e b b g e e e f e b e f b e

424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

58 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|----------|

☐ 22. Document ID: US 5869469 A

L19: Entry 22 of 27

File: USPT

Feb 9, 1999

US-PAT-NO: 5869469

DOCUMENT-IDENTIFIER: US 5869469 A

TITLE: Phosphonocarboxylate compounds for treating amyloidosis

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|-------------------|----------|-------|----------|---------|
| Szarek; Walter A. | Kingston | | | CA |
| Kong; Xianqi | Kingston | | | CA |

US-CL-CURRENT: 514/120

ABSTRACT:

Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.

25 Claims, 0 Drawing figures

Exemplary Claim Number: 1

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | Claims | KWIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--------|------|----------|

☐ 23. Document ID: US 5858326 A

L19: Entry 23 of 27

File: USPT

Jan 12, 1999

h e b b g e e f e b e f b e

US-PAT-NO: 5858326

DOCUMENT-IDENTIFIER: US 5858326 A

TITLE: Methods of increasing amyloid deposition

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|----------|-------|----------|---------|
| Kisilevsky; Robert | Kingston | | | CA |
| Szarek; Walter | Kingston | | | CA |
| Weaver; Donald | Kingston | | | CA |
| Fraser; Paul | Toronto | | | CA |
| Kong; Xianqi | Kingston | | | CA |

US-CL-CURRENT: 424/9.2; 424/78.31, 424/78.35, 435/7.8, 435/7.92, 435/7.93, 435/7.95,
514/772.4, 530/350, 800/9

ABSTRACT:

In vivo and in vitro methods of increasing amyloid deposition using amyloid-enhancing compounds are described. Methods of forming amyloid fibrils and screening for agents useful in treating amyloidosis are also described. Animals having non-naturally occurring amyloid deposits produced using the amyloid-enhancing compounds even further are described.

5 Claims, 2 Drawing figures

Exemplary Claim Number: 5

Number of Drawing Sheets: 2

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|------|----------|

☐ 24. Document ID: US 5840294 A

L19: Entry 24 of 27

File: USPT

Nov 24, 1998

US-PAT-NO: 5840294

DOCUMENT-IDENTIFIER: US 5840294 A

**** See image for Certificate of Correction ****

TITLE: Method for treating amyloidosis

DATE-ISSUED: November 24, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|----------|-------|----------|---------|
| Kisilevsky; Robert | Kingston | | | CA |
| Szarek; Walter | Kingston | | | CA |
| Weaver; Donald | Kingston | | | CA |

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441,
424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

h e b b g e e e f e b ef b e

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

66 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KNIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--------|------|----------|

☐ 25. Document ID: US 5728375 A

L19: Entry 25 of 27

File: USPT

Mar 17, 1998

US-PAT-NO: 5728375

DOCUMENT-IDENTIFIER: US 5728375 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|----------|-------|----------|---------|
| Kisilevsky; Robert | Kingston | | | CA |
| Szarek; Walter | Kingston | | | CA |
| Weaver; Donald | Kingston | | | CA |

US-CL-CURRENT: 424/78.31; 424/450, 424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

71 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

| Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KNIC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--------|------|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--------|------|----------|

☐ 26. Document ID: US 5643562 A

h e b b g e e e f e b e f b e

L19: Entry 26 of 27

File: USPT

Jul 1, 1997

US-PAT-NO: 5643562

DOCUMENT-IDENTIFIER: US 5643562 A

TITLE: Method for treating amyloidosis

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|--------------------|----------|-------|----------|---------|
| Kisilevsky; Robert | Kingston | | | CA |
| Szarek; Walter | Kingston | | | CA |
| Weaver; Donald | Kingston | | | CA |

US-CL-CURRENT: 424/78.31; 424/423, 424/427, 424/430, 424/434, 424/436, 424/441,
424/78.35, 514/772.4, 526/286, 526/287

ABSTRACT:

Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.

55 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWC | Draw Des |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|----------|

☐ 27. Document ID: US 5276059 A

L19: Entry 27 of 27

File: USPT

Jan 4, 1994

US-PAT-NO: 5276059

DOCUMENT-IDENTIFIER: US 5276059 A

**** See image for Certificate of Correction ****

TITLE: Inhibition of diseases associated with amyloid formation

DATE-ISSUED: January 4, 1994

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|----------------|----------|-------|----------|---------|
| Caughey; Byron | Hamilton | MT | | |
| Race; Richard | Hamilton | MT | | |

US-CL-CURRENT: 514/647

h e b b g e e f e b ef b e

ABSTRACT:

The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.

34 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

| Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWC | Draw. Des. |
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|------------|
|------|-------|----------|-------|--------|----------------|------|-----------|--|--|--------|-----|------------|

| | | | | | |
|-------|---------------------|-------|----------|-----------|---------------|
| Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS |
|-------|---------------------|-------|----------|-----------|---------------|

| | |
|--------------|-----------|
| Terms | Documents |
| L15 AND AScr | 27 |

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for PrPSc AND vaccine Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-3 of 3

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Vorberg I, Raines A, Story B, Priola SA.](#)

[Related Articles, Links](#)



Susceptibility of common fibroblast cell lines to transmissible spongiform encephalopathy agents.

J Infect Dis. 2004 Feb 1;189(3):431-9. Epub 2004 Jan 21.

PMID: 14745700 [PubMed - indexed for MEDLINE]

☐ 2: [Zanusso G, Casalone C, Acutis P, Bozzetta E, Farinazzo A, Gelati M, Fiorini M, Forloni G, Sy MS, Monaco S, Caramelli M.](#)

[Related Articles, Links](#)



Molecular analysis of iatrogenic scrapie in Italy.

J Gen Virol. 2003 Apr;84(Pt 4):1047-52.

PMID: 12655108 [PubMed - indexed for MEDLINE]

☐ 3: [Harmeyer S, Pfaff E, Groschup MH.](#)

[Related Articles, Links](#)



Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants.

J Gen Virol. 1998 Apr;79 (Pt 4):937-45.

PMID: 9568991 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Am J Pathol. 2002 Jul;161(1):13-7.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Immunization delays the onset of prion disease in mice.

Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T.

Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA.

The outbreak of new variant Creutzfeldt-Jakob disease has raised the specter of a potentially large population being at risk to develop this prionosis. None of the prionoses currently have an effective treatment. Recently, vaccination has been shown to be effective in mouse models of another neurodegenerative condition, namely Alzheimer's disease. Here we report that vaccination with recombinant mouse prion protein delays the onset of prion disease in mice. Vaccination was performed both before peripheral prion exposure and after exposure. A delay in disease onset was seen in both groups, but was more prolonged in animals immunized before exposure. The increase in the incubation period closely correlated with the anti-prion protein antibody titer. This promising finding suggests that a similar approach may work in humans or other mammalian species at risk for prion disease.

PMID: 12107084 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for Sigurdsson AND 2003 Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

Display Summary Show: 500 Sort Send to Text
 Items 1-55 of 55 One page.

☐ 1: [Arason GJ, Bodvarsson S, Sigurdarson ST, Sigurdsson G, Thorgerirsson G, Gudmundsson S, Kramer J, Fust G.](#) Related Articles, Links

An age-associated decrease in the frequency of C4B*Q0 indicates that null alleles of complement may affect health or survival.
 Ann N Y Acad Sci. 2003 Dec;1010:496-9.
 PMID: 15033778 [PubMed - indexed for MEDLINE]

☐ 2: [Einksson SO, Pereira PN, Swift EJ Jr, Heymann HO, Sigurdsson A.](#) Related Articles, Links

Effects of saliva contamination on resin-resin bond strength.
 Dent Mater. 2004 Jan;20(1):37-44.
 PMID: 14698772 [PubMed - indexed for MEDLINE]

☐ 3: [Engelen JW, Kooistra MP, Canninga-van Dijk MR, Toonstra J, Sigurdsson V.](#) Related Articles, Links

[Nephrogenic fibrosing dermopathy]
 Ned Tijdschr Geneesk. 2003 Dec 6;147(49):2435-8. Dutch.
 PMID: 14694555 [PubMed - indexed for MEDLINE]

☐ 4: [Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K.](#) Related Articles, Links

Linkage of Osteoporosis to Chromosome 20p12 and Association to BMP2.
 PLoS Biol. 2003 Dec;1(3):E69. Epub 2003 Nov 03.
 PMID: 14691541 [PubMed - in process]

☐ 5: [Stefansson E, Zetterstrom C, Ehlers N, Kuilgaard JF, la Cour M, Sigurdsson H, Gudmundsdottir E, Prause JU, Heijl A.](#) Related Articles, Links

Nordic research in ophthalmology.
 Acta Ophthalmol Scand. 2003 Dec;81(6):556-66. Review.
 PMID: 14641254 [PubMed - indexed for MEDLINE]

☐ 6: [Sigurdsson HO.](#) Related Articles, Links

Career development programs at Landspítali University Hospital.
 Nurs Leadersh Forum. 2003 Fall;8(1):40-4.
 PMID: 14649131 [PubMed - indexed for MEDLINE]




















☐ 7: [Hollins M, Sigurdsson A, Morris KA.](#) Related Articles, Links

Local vibrotactile and pain sensitivities are negatively related in temporomandibular disorders.
 J Pain. 2001 Feb;2(1):46-56.
 PMID: 14622785 [PubMed]

☐ 8: [Geirsson J, Sigurdsson A.](#) Related Articles, Links


Posts in endodontically treated teeth.
 J Esthet Restor Dent. 2003;15(5):313-8. No abstract available.
 PMID: 14620662 [PubMed]


☐ 9: [Lovmar L, Fredriksson M, Liljedahl U, Sigurdsson S, Syvanen AC.](#) Related Articles, Links


-  **Quantitative evaluation by minisequencing and microarrays reveals accurate multiplexed SNP genotyping of whole genome amplified DNA.**
Nucleic Acids Res. 2003 Nov 1;31(21):e129.
PMID: 14576329 [PubMed - indexed for MEDLINE]
-  **10:** [Schiemann O, Fritscher J, Kisseleva N, Sigurdsson ST, Prisner TF.](#) Related Articles, Links
-  **Structural investigation of a high-affinity MnII binding site in the hammerhead ribozyme by EPR spectroscopy and DFT calculations. Effects of neomycin B on metal-ion binding.**
Chembiochem. 2003 Oct 6;4(10):1057-65.
PMID: 14523924 [PubMed - in process]
-  **11:** [Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, Wisniewski T.](#) Related Articles, Links
-  **Copper chelation delays the onset of prion disease.**
J Biol Chem. 2003 Nov 21;278(47):46199-202. Epub 2003 Sep 30.
PMID: 14519758 [PubMed - indexed for MEDLINE]
-  **12:** [Getz L, Sigurdsson JA, Hetlevik I.](#) Related Articles, Links
-  **Is opportunistic disease prevention in the consultation ethically justifiable?**
BMJ. 2003 Aug 30;327(7413):498-500. No abstract available.
PMID: 12946974 [PubMed - indexed for MEDLINE]
-  **13:** [Wikesjo UM, Lim WH, Razi SS, Sigurdsson TJ, Lee MB, Tatakis DN, Hardwick WR.](#) Related Articles, Links
-  **Periodontal repair in dogs: a bioabsorbable calcium carbonate coral implant enhances space provision for alveolar bone regeneration in conjunction with guided tissue regeneration.**
J Periodontol. 2003 Jul;74(7):957-64.
PMID: 12931757 [PubMed - indexed for MEDLINE]
-  **14:** [Olsen GL, Louie EA, Drobny GP, Sigurdsson ST.](#) Related Articles, Links
-  **Determination of DNA minor groove width in distamycin-DNA complexes by solid-state NMR.**
Nucleic Acids Res. 2003 Sep 1;31(17):5084-9.
PMID: 12930959 [PubMed - indexed for MEDLINE]
-  **15:** [Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA.](#) Related Articles, Links
-  **Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol.**
Br J Dermatol. 2003 Jul;149(1):131-7. Review.
PMID: 12890206 [PubMed - indexed for MEDLINE]
-  **16:** [Sigurdsson EL, Thorgeirsson G.](#) Related Articles, Links
-  **Primary prevention of cardiovascular diseases.**
Scand J Prim Health Care. 2003 Jun;21(2):68-74. Review.
PMID: 12877367 [PubMed - indexed for MEDLINE]
-  **17:** [Sigurdsson JA.](#) Related Articles, Links
-  **The GP's role in maternity care.**
Scand J Prim Health Care. 2003 Jun;21(2):65. No abstract available.
PMID: 12877365 [PubMed - indexed for MEDLINE]
-  **18:** [Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JJ, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH.](#) Related Articles, Links
-  **Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging.**

Magn Reson Med. 2003 Aug;50(2):293-302.
PMID: 12876705 [PubMed - indexed for MEDLINE]


-  **19:** [Sigurdsson S, Richer HB, Hansen BM, Stairs IH, Thorsett SE.](#) [Related Articles, Links](#)


 **A young white dwarf companion to pulsar B1620-26: evidence for early planet formation.**
Science. 2003 Jul 11;301(5630):193-6.
PMID: 12855802 [PubMed]


-  **20:** [Reynisdottir I, Thorleifsson G, Benediktsson R, Sigurdsson G, Emilsson V, Einarsson AS, Hjorleifsdottir EE, Orlygsdottir GT, Bjornsdottir GT, Saemundsdottir J, Halldorsson S, Hrafnkelsdottir S, Sigurjonsdottir SB, Steinsdottir S, Martin M, Kochan JP, Rhees BK, Grant SF, Frigge ML, Kong A, Gudnason V, Stefansson K, Gulcher JR.](#) [Related Articles, Links](#)


 **Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2.**
Am J Hum Genet. 2003 Aug;73(2):323-35. Epub 2003 Jul 08.
PMID: 12851856 [PubMed - indexed for MEDLINE]


-  **21:** [Doyere V, Schafe GE, Sigurdsson T, LeDoux JE.](#) [Related Articles, Links](#)


 **Long-term potentiation in freely moving rats reveals asymmetries in thalamic and cortical inputs to the lateral amygdala.**
Eur J Neurosci. 2003 Jun;17(12):2703-15.
PMID: 12823477 [PubMed - indexed for MEDLINE]


-  **22:** [Sigurdardottir M, Sigurdsson H, Barkardottir RB, Kristjansdottir S, Agnarsson BA.](#) [Related Articles, Links](#)

 **Lymphoid tumours of the ocular adnexa: a morphologic and genotypic study of 15 cases.**
Acta Ophthalmol Scand. 2003 Jun;81(3):299-303.
PMID: 12780412 [PubMed - indexed for MEDLINE]


-  **23:** [Sigurdsson G, Yannopoulos D, McKnite SH, Lurie KG.](#) [Related Articles, Links](#)

 **Cardiorespiratory interactions and blood flow generation during cardiac arrest and other states of low blood flow.**
Curr Opin Crit Care. 2003 Jun;9(3):183-8. Review.
PMID: 12771667 [PubMed - indexed for MEDLINE]


-  **24:** [van Kooij B, van Dijk MC, de Boer J, Sigurdsson V, Rothova A.](#) [Related Articles, Links](#)


 **Is granuloma annulare related to intermediate uveitis with retinal vasculitis?**
Br J Ophthalmol. 2003 Jun;87(6):763-6.
PMID: 12770977 [PubMed - indexed for MEDLINE]











-  **25:** [Sigurdsson U, Adolphson P.](#) [Related Articles, Links](#)




















 **[Few injuries among Swedish telemark skiers, but equipment requires careful consideration]**
Lakartidningen. 2003 Apr 17;100(16):1440-3. Swedish.
PMID: 12756712 [PubMed - indexed for MEDLINE]









-  **26:** [Borda EJ, Markley JC, Sigurdsson ST.](#) [Related Articles, Links](#)

 **Zinc-dependent cleavage in the catalytic core of the hammerhead ribozyme: evidence for a pH-dependent conformational change.**
Nucleic Acids Res. 2003 May 15;31(10):2595-600.
PMID: 12736309 [PubMed - indexed for MEDLINE]

-  **27:** [Gudmundsdottir T, Tryggvadottir L, Allende M, Mast TC, Briem H, Sigurdsson K.](#) [Related Articles, Links](#)

-  Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial.
Acta Obstet Gynecol Scand. 2003 Apr;82(4):345-50.
PMID: 12716319 [PubMed - indexed for MEDLINE]
-  **28:** [Sigurdsson S, Stromberg R.](#) [Related Articles, Links](#)
Side reactions in the H-phosphonate approach to oligonucleotide synthesis: a kinetic investigation on bisacylphosphite formation and 5'-O-acylation.
Nucleosides Nucleotides Nucleic Acids. 2003;22(1):1-12.
PMID: 12708797 [PubMed - indexed for MEDLINE]
-  **29:** [Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir L.](#) [Related Articles, Links](#)
Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model.
Infect Immun. 2003 May;71(5):2956-9.
PMID: 12704178 [PubMed - indexed for MEDLINE]
-  **30:** [Huomonen S, Lenander-Lumikari M, Sigurdsson A, Orstavik D.](#) [Related Articles, Links](#)
Healing of apical periodontitis after endodontic treatment: a comparison between a silicone-based and a zinc oxide-eugenol-based sealer.
Int Endod J. 2003 Apr;36(4):296-301.
PMID: 12702125 [PubMed - indexed for MEDLINE]
-  **31:** [Mikaelsdottir EK, Benediktsdottir KR, Olafsdottir K, Arnadottir T, Ragnarsson GB, Olafsson K, Sigurdsson K, Kristjansdottir GS, Imslund AK, Ogmundsdottir HM, Rafnar T.](#) [Related Articles, Links](#)
HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958-1960 and 1995-1996.
Gynecol Oncol. 2003 Apr;89(1):22-30.
PMID: 12694650 [PubMed - indexed for MEDLINE]
-  **32:** [Edwards TE, Sigurdsson ST.](#) [Related Articles, Links](#)
EPR spectroscopic analysis of TAR RNA-metal ion interactions.
Biochem Biophys Res Commun. 2003 Apr 4;303(2):721-5.
PMID: 12659878 [PubMed - indexed for MEDLINE]
-  **33:** [Kristmundsdottir T, Sigurdsson P, Thormar H.](#) [Related Articles, Links](#)
Effect of buffers on the properties of microbicidal hydrogels containing monoglyceride as the active ingredient.
Drug Dev Ind Pharm. 2003 Feb;29(2):121-9.
PMID: 12648008 [PubMed - indexed for MEDLINE]
-  **34:** [Khan S, Orenstein SR, Di Lorenzo C, Kocoshis SA, Putnam PE, Sigurdsson L, Shalaby TM.](#) [Related Articles, Links](#)
Eosinophilic esophagitis: strictures, impactions, dysphagia.
Dig Dis Sci. 2003 Jan;48(1):22-9.
PMID: 12645786 [PubMed - indexed for MEDLINE]
-  **35:** [Schiemann O, Weber A, Edwards TE, Prisner TF, Sigurdsson ST.](#) [Related Articles, Links](#)
Nanometer distance measurements on RNA using PELDOR.
J Am Chem Soc. 2003 Mar 26;125(12):3434-5. No abstract available.
PMID: 12643697 [PubMed - indexed for MEDLINE]
-  **36:** [Chirakul P, Sigurdsson ST.](#) [Related Articles, Links](#)
Stereospecific syntheses of 3'-deuterated pyrimidine nucleosides and their site-specific incorporation into DNA.
Org Lett. 2003 Mar 20;5(6):917-9.
PMID: 12633105 [PubMed - indexed for MEDLINE]

-  **37:** [Booher MA, Wisniewski J, Smith BW, Sigurdsson A.](#) [Related Articles](#), [Links](#)
 **Comparison of reporting systems to determine concussion incidence in NCAA Division I collegiate football.**
 Clin J Sport Med. 2003 Mar;13(2):93-5.
 PMID: 12629426 [PubMed - indexed for MEDLINE]
-  **38:** [Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir H, Stefansdottir I, Sigvaldason H, Gudnason V.](#) [Related Articles](#), [Links](#)
 **Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate.**
 Scand Cardiovasc J. 2002 Dec;36(6):337-41.
 PMID: 12626199 [PubMed - indexed for MEDLINE]
-  **39:** [Hiltebrand LB, Krejci V, tenHoevel ME, Banic A, Sigurdsson GH.](#) [Related Articles](#), [Links](#)
 **Redistribution of microcirculatory blood flow within the intestinal wall during sepsis and general anesthesia.**
 Anesthesiology. 2003 Mar;98(3):658-69.
 PMID: 12606910 [PubMed - indexed for MEDLINE]
-  **40:** [Thorsson B, Sigurdsson G, Gudnason V.](#) [Related Articles](#), [Links](#)
 **Systematic family screening for familial hypercholesterolemia in Iceland.**
 Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):335-8.
 PMID: 12588780 [PubMed - indexed for MEDLINE]
-  **41:** [Svantesson C, Drefeldt B, Sigurdsson S, Larsson A, Brochard L, Jonson B.](#) [Related Articles](#), [Links](#)
 **A single computer-controlled mechanical insufflation allows determination of the pressure-volume relationship of the respiratory system.**
 J Clin Monit Comput. 1999 Jan;15(1):9-16.
 PMID: 12578056 [PubMed - indexed for MEDLINE]
-  **42:** [Krejci V, Hiltebrand LB, Erni D, Sigurdsson GH.](#) [Related Articles](#), [Links](#)
 **Endothelin receptor antagonist bosentan improves microcirculatory blood flow in splanchnic organs in septic shock.**
 Crit Care Med. 2003 Jan;31(1):203-10.
 PMID: 12545016 [PubMed - indexed for MEDLINE]
-  **43:** [Kristjansson K, Sigurdsson JA, Lissner L, Sundh V, Bengtsson C.](#) [Related Articles](#), [Links](#)
 **Blood pressure and pulse pressure development in a population sample of women with special reference to basal body mass and distribution of body fat and their changes during 24 years.**
 Int J Obes Relat Metab Disord. 2003 Jan;27(1):128-33.
 PMID: 12532164 [PubMed - indexed for MEDLINE]
-  **44:** [Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kasesak RJ, Kasesak R, Carp R, Meeker HC, Frangione B, Wisniewski T.](#) [Related Articles](#), [Links](#)
 **Anti-prion antibodies for prophylaxis following prion exposure in mice.**
 Neurosci Lett. 2003 Jan 23;336(3):185-7.
 PMID: 12505623 [PubMed - indexed for MEDLINE]
-  **45:** [Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr.](#) [Related Articles](#), [Links](#)
 **Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.**
 Neurobiol Dis. 2002 Nov;11(2):315-29.
 PMID: 12505424 [PubMed - indexed for MEDLINE]
-  **46:** [Arason VA, Sigurdsson JA, Kristinsson KG, Gudmundsson S.](#) [Related Articles](#), [Links](#)

-  Tympanostomy tube placements, sociodemographic factors and parental expectations for management of acute otitis media in Iceland.
Pediatr Infect Dis J. 2002 Dec;21(12):1110-5.
PMID: 12488659 [PubMed - indexed for MEDLINE]
-  **47:** [Sigurdsson EM, Wisniewski T, Frangione B.](#) [Related Articles, Links](#)
-  A safer vaccine for Alzheimer's disease?
Neurobiol Aging. 2002 Nov-Dec;23(6):1001-8. Review.
PMID: 12470795 [PubMed - indexed for MEDLINE]
-  **48:** [Card SJ, Sigurdsson A, Orstavik D, Trope M.](#) [Related Articles, Links](#)
-  The effectiveness of increased apical enlargement in reducing intracanal bacteria.
J Endod. 2002 Nov;28(11):779-83.
PMID: 12470024 [PubMed - indexed for MEDLINE]
-  **49:** [Costello NL, Bragdon EE, Light KC, Sigurdsson A, Bunting S, Grewen K, Maixner W.](#) [Related Articles, Links](#)
-  Temporomandibular disorder and optimism: relationships to ischemic pain sensitivity and interleukin-6.
Pain. 2002 Nov;100(1-2):99-110.
PMID: 12435463 [PubMed - indexed for MEDLINE]
-  **50:** [Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V, Reykjavik Cohort Study.](#) [Related Articles, Links](#)
-  Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study.
Eur Heart J. 2002 Nov;23(21):1655-63.
PMID: 12398822 [PubMed - indexed for MEDLINE]
-  **51:** [Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG.](#) [Related Articles, Links](#)
-  Clonal spread of resistant pneumococci despite diminished antimicrobial use.
Microb Drug Resist. 2002 Fall;8(3):187-92.
PMID: 12363007 [PubMed - indexed for MEDLINE]
-  **52:** [Van Komen S, Petukhova G, Sigurdsson S, Sung P.](#) [Related Articles, Links](#)
-  Functional cross-talk among Rad51, Rad54, and replication protein A in heteroduplex DNA joint formation.
J Biol Chem. 2002 Nov 15;277(46):43578-87. Epub 2002 Sep 10.
PMID: 12226081 [PubMed - indexed for MEDLINE]
-  **53:** [Sigurdsson EM, Wisniewski T, Frangione B.](#) [Related Articles, Links](#)
-  Infectivity of amyloid diseases.
Trends Mol Med. 2002 Sep;8(9):411-3.
PMID: 12223307 [PubMed - indexed for MEDLINE]
-  **54:** [Sigurdsson S, Van Komen S, Petukhova G, Sung P.](#) [Related Articles, Links](#)
-  Homologous DNA pairing by human recombination factors Rad51 and Rad54.
J Biol Chem. 2002 Nov 8;277(45):42790-4. Epub 2002 Aug 29.
PMID: 12205100 [PubMed - indexed for MEDLINE]
-  **55:** [Wisniewski T, Brown DR, Sigurdsson EM.](#) [Related Articles, Links](#)
-  Therapeutics in Alzheimer's and prion diseases.
Biochem Soc Trans. 2002 Aug;30(4):574-8. Review.
PMID: 12196140 [PubMed - indexed for MEDLINE]

Display

Summary

Show:

500


Sort

Send to

Text

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Neurosci Lett. 2003 Jan 23;336(3):185-7.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Full Text Article](#)

Anti-prion antibodies for prophylaxis following prion exposure in mice.

Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T.

Department of Psychiatry, New York University School of Medicine, Millhauser Laboratory, 550 First Avenue, New York, NY 10016, USA.

Prion disease is characterized by a conformational change of the normal form of the prion protein (PrP(C)) to the scrapie-associated form (PrP(Sc)). Since the emergence of new variant Creutzfeldt-Jakob disease a potentially large human population is at risk for developing prion disease. Currently, no effective treatment or form of post-exposure prophylaxis is available for prion disease. We recently showed that active immunization with recombinant PrP prolongs the incubation period of scrapie. Here we show that anti-PrP antibodies following prion exposure are effective at increasing the incubation period of the infection. Stimulation of the immune system is an important therapeutic target for the prion diseases, as well as for other neurodegenerative illnesses characterized by abnormal protein conformation.

PMID: 12505623 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for Sigurdsson AND 2002 Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-58 of 58

One page.

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities




















PubMed Services



















Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Caddy



















Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central


- ☐ 1: [Stefansson E, Zetterstrom C, Ehlers N, Kiilgaard JF, la Cour M, Sigurdsson H, Gudmundsdottir E, Prause JU, Heijl A.](#) Related Articles, Links
 Nordic research in ophthalmology.
 Acta Ophthalmol Scand. 2003 Dec;81(6):556-66. Review.
 PMID: 14641254 [PubMed - indexed for MEDLINE]
- ☐ 2: [Booher MA, Wisniewski J, Smith BW, Sigurdsson A.](#) Related Articles, Links
 Comparison of reporting systems to determine concussion incidence in NCAA Division I collegiate football.
 Clin J Sport Med. 2003 Mar;13(2):93-5.
 PMID: 12629426 [PubMed - indexed for MEDLINE]
- ☐ 3: [Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir II, Stefansdottir I, Sigvaldason H, Gudnason V.](#) Related Articles, Links
 Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate.
 Scand Cardiovasc J. 2002 Dec;36(6):337-41.
 PMID: 12626199 [PubMed - indexed for MEDLINE]
- ☐ 4: [Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T.](#) Related Articles, Links
 Anti-prion antibodies for prophylaxis following prion exposure in mice.
 Neurosci Lett. 2003 Jan 23;336(3):185-7.
 PMID: 12505623 [PubMed - indexed for MEDLINE]
- ☐ 5: [Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr.](#) Related Articles, Links
 Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.
 Neurobiol Dis. 2002 Nov;11(2):315-29.
 PMID: 12505424 [PubMed - indexed for MEDLINE]
- ☐ 6: [Arason VA, Sigurdsson JA, Kristinsson KG, Gudmundsson S.](#) Related Articles, Links
 Tympanostomy tube placements, sociodemographic factors and parental expectations for management of acute otitis media in Iceland.
 Pediatr Infect Dis J. 2002 Dec;21(12):1110-5.
 PMID: 12488659 [PubMed - indexed for MEDLINE]
- ☐ 7: [Sigurdsson EM, Wisniewski T, Frangione B.](#) Related Articles, Links
 A safer vaccine for Alzheimer's disease?
 Neurobiol Aging. 2002 Nov-Dec;23(6):1001-8. Review.
 PMID: 12470795 [PubMed - indexed for MEDLINE]
- ☐ 8: [Card SJ, Sigurdsson A, Orstavik D, Trope M.](#) Related Articles, Links
 The effectiveness of increased apical enlargement in reducing intracanal bacteria.
 J Endod. 2002 Nov;28(11):779-83.
 PMID: 12470024 [PubMed - indexed for MEDLINE]

-  **9:** Costello NL, Bragdon EE, Light KC, Sigurdsson A, Bunting S, Grewen K, Maixner W. [Related Articles](#), [Links](#)
-  **Temporomandibular disorder and optimism: relationships to ischemic pain sensitivity and interleukin-6.**
Pain. 2002 Nov;100(1-2):99-110.
PMID: 12435463 [PubMed - indexed for MEDLINE]
-  **10:** Luginbuhl M, Reichlin F, Sigurdsson GH, Zbinden AM, Petersen-Felix S. [Related Articles](#), [Links](#)
-  **Prediction of the haemodynamic response to tracheal intubation: comparison of laser-Doppler skin vasomotor reflex and pulse wave reflex.**
Br J Anaesth. 2002 Sep;89(3):389-97.
PMID: 12402716 [PubMed - indexed for MEDLINE]
-  **11:** Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V, Reykjavik Cohort Study. [Related Articles](#), [Links](#)
-  **Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study.**
Eur Heart J. 2002 Nov;23(21):1655-63.
PMID: 12398822 [PubMed - indexed for MEDLINE]
-  **12:** Rupert PB, Massey AP, Sigurdsson ST, Ferre-D'Amare AR. [Related Articles](#), [Links](#)
-  **Transition state stabilization by a catalytic RNA.**
Science. 2002 Nov 15;298(5597):1421-4. Epub 2002 Oct 10.
PMID: 12376595 [PubMed - indexed for MEDLINE]
-  **13:** Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. [Related Articles](#), [Links](#)
-  **Clonal spread of resistant pneumococci despite diminished antimicrobial use.**
Microb Drug Resist. 2002 Fall;8(3):187-92.
PMID: 12363007 [PubMed - indexed for MEDLINE]
-  **14:** Chattipakorn SC, Sigurdsson A, Light AR, Narhi M, Maixner W. [Related Articles](#), [Links](#)
-  **Trigeminal c-Fos expression and behavioral responses to pulpal inflammation in ferrets.**
Pain. 2002 Sep;99(1-2):61-9.
PMID: 12237184 [PubMed - indexed for MEDLINE]
-  **15:** Van Komen S, Petukhova G, Sigurdsson S, Sung P. [Related Articles](#), [Links](#)
-  **Functional cross-talk among Rad51, Rad54, and replication protein A in heteroduplex DNA joint formation.**
J Biol Chem. 2002 Nov 15;277(46):43578-87. Epub 2002 Sep 10.
PMID: 12226081 [PubMed - indexed for MEDLINE]
-  **16:** Sigurdsson EM, Wisniewski T, Frangione B. [Related Articles](#), [Links](#)
-  **Infectivity of amyloid diseases.**
Trends Mol Med. 2002 Sep;8(9):411-3.
PMID: 12223307 [PubMed - indexed for MEDLINE]
-  **17:** Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T. [Related Articles](#), [Links](#)
-  **Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice.**
J Alzheimers Dis. 2001 Feb;3(1):23-30.
PMID: 12214069 [PubMed - as supplied by publisher]
-  **18:** Sigurdsson S, Van Komen S, Petukhova G, Sung P. [Related Articles](#), [Links](#)


-  **Homologous DNA pairing by human recombination factors Rad51 and Rad54.**
J Biol Chem. 2002 Nov 8;277(45):42790-4. Epub 2002 Aug 29.
PMID: 12205100 [PubMed - indexed for MEDLINE]
-  **19:** [Wisniewski T, Brown DR, Sigurdsson EM.](#) [Related Articles, Links](#)
-  **Therapeutics in Alzheimer's and prion diseases.**
Biochem Soc Trans. 2002 Aug;30(4):574-8. Review.
PMID: 12196140 [PubMed - indexed for MEDLINE]
-  **20:** [Wisniewski T, Sigurdsson EM.](#) [Related Articles, Links](#)
-  **Immunization treatment approaches in Alzheimer's and prion diseases.**
Curr Neurol Neurosci Rep. 2002 Sep;2(5):400-4. Review.
PMID: 12169219 [PubMed - indexed for MEDLINE]
-  **21:** [Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K.](#) [Related Articles, Links](#)
-  **Neuregulin 1 and susceptibility to schizophrenia.**
Am J Hum Genet. 2002 Oct;71(4):877-92. Epub 2002 Jul 23.
PMID: 12145742 [PubMed - indexed for MEDLINE]
-  **22:** [Ekstrom DN, Sigurdsson HO.](#) [Related Articles, Links](#)
-  **An international collaboration in nursing education viewed through the lens of critical social theory.**
J Nurs Educ. 2002 Jul;41(7):289-94.
PMID: 12137119 [PubMed - indexed for MEDLINE]
-  **23:** [Lindroos K, Sigurdsson S, Johansson K, Ronnblom L, Syvanen AC.](#) [Related Articles, Links](#)
-  **Multiplex SNP genotyping in pooled DNA samples by a four-colour microarray system.**
Nucleic Acids Res. 2002 Jul 15;30(14):e70.
PMID: 12136118 [PubMed - indexed for MEDLINE]
-  **24:** [Sigurdsson EM, Brown DR, Daniels M, Kascak RJ, Kascak R, Carp R, Meeker HC, Frangione B, Wisniewski T.](#) [Related Articles, Links](#)
-  **Immunization delays the onset of prion disease in mice.**
Am J Pathol. 2002 Jul;161(1):13-7.
PMID: 12107084 [PubMed - indexed for MEDLINE]
-  **25:** [Sigurdsson EL, Jonsson JS, Thorgeirsson G.](#) [Related Articles, Links](#)
-  **Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland.**
Scand J Prim Health Care. 2002 Mar;20(1):10-5.
PMID: 12086276 [PubMed - indexed for MEDLINE]
-  **26:** [Suh YI, Lundgren T, Sigurdsson T, Riggs M, Crigger M.](#) [Related Articles, Links](#)
-  **Probing bone level measurements for determination of the depths of Class II furcation defects.**
J Periodontol. 2002 Jun;73(6):637-42.
PMID: 12083537 [PubMed - indexed for MEDLINE]
-  **27:** [Edwards TE, Okonogi TM, Sigurdsson ST.](#) [Related Articles, Links](#)

-  Investigation of RNA-protein and RNA-metal ion interactions by electron paramagnetic resonance spectroscopy. The HIV TAR-Tat motif.
Chem Biol. 2002 Jun;9(6):699-706.
PMID: 12079781 [PubMed - indexed for MEDLINE]
-  **28:** [Sigurdsson E, Van Os J, Fombonne E.](#) [Related Articles, Links](#)
 Are impaired childhood motor skills a risk factor for adolescent anxiety? Results from the 1958 U.K. birth cohort and the National Child Development Study.
Am J Psychiatry. 2002 Jun;159(6):1044-6.
PMID: 12042195 [PubMed - indexed for MEDLINE]
-  **29:** [Karadottir H, Lenoir L, Barbierato B, Bogle M, Riggs M, Sigurdsson T, Crigger M, Egelberg J.](#) [Related Articles, Links](#)
 Pain experienced by patients during periodontal maintenance treatment.
J Periodontol. 2002 May;73(5):536-42.
PMID: 12027257 [PubMed - indexed for MEDLINE]
-  **30:** [Bragdon EE, Light KC, Costello NL, Sigurdsson A, Bunting S, Bhalang K, Maixner W.](#) [Related Articles, Links](#)
 Group differences in pain modulation: pain-free women compared to pain-free men and to women with TMD.
Pain. 2002 Apr;96(3):227-37.
PMID: 11972994 [PubMed - indexed for MEDLINE]
-  **31:** [Poser CM.](#) [Related Articles, Links](#)
 Notes on the history of the prion diseases. Part II.
Clin Neurol Neurosurg. 2002 May;104(2):77-86.
PMID: 11932035 [PubMed - indexed for MEDLINE]
-  **32:** [Tan KS, Liu LL.](#) [Related Articles, Links](#)
 Description of a new species of Thais (Mollusca: Neogastropoda: Muricidae) from Taiwan, based on morphological and allozyme analyses.
Zoolog Sci. 2001 Dec;18(9):1275-89.
PMID: 11911084 [PubMed - indexed for MEDLINE]
-  **33:** [Hardarson A, Sigurdsson G, Olafsdottir E, Dallongeville J, Berg AL, Arnadottir M.](#) [Related Articles, Links](#)
 Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients.
J Intern Med. 2001 Dec;250(6):530-4.
PMID: 11902822 [PubMed - indexed for MEDLINE]
-  **34:** [Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T.](#) [Related Articles, Links](#)
 Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.
Eur J Biochem. 2002 Mar;269(6):1670-7.
PMID: 11895437 [PubMed - indexed for MEDLINE]
-  **35:** [Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW.](#) [Related Articles, Links](#)
 The long term results of endoscopic surveillance of premalignant gastric lesions.
Gut. 2002 Mar;50(3):378-81.
PMID: 11839718 [PubMed - indexed for MEDLINE]
-  **36:** [Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, Jakobsson F, Einarsson E, Agnarsson U, Shkolny D, Einarsson G, Gudjonsdottir HM, Valdimarsson EM, Einarsson OB, Thorgeirsson](#) [Related Articles, Links](#)


G. Hadzic R. Jonsdottir S. Reynisdottir ST. Bjarnadottir SM. Gudmundsdottir T. Gudlaugsdottir GJ. Gill R. Lindpaintner K. Sainz J. Hannesson HH. Sigurdsson GT. Frigge ML. Kong A. Gudnason V. Stefansson K. Gulcher JR.

-  **Localization of a susceptibility gene for common forms of stroke to 5q12.**
Am J Hum Genet. 2002 Mar;70(3):593-603. Epub 2002 Feb 06.
PMID: 11833004 [PubMed - indexed for MEDLINE]


 **37:** Masson M. Thorsteinsson T. Sigurdsson TH. Loftsson T. [Related Articles, Links](#)

-  **Lipophilic metronidazole derivatives and their absorption through hairless mouse skin.**
Pharmazie. 2000 May;55(5):369-71.
PMID: 11828618 [PubMed - indexed for MEDLINE]


 **38:** Chirakul P. Litzer JR. Sigurdsson STh. [Related Articles, Links](#)


-  **Preparation of base-deuterated 2'-deoxyadenosine nucleosides and their site-specific incorporation into DNA.**
Nucleosides Nucleotides Nucleic Acids. 2001 Dec;20(12):1903-13.
PMID: 11794796 [PubMed - indexed for MEDLINE]


 **39:** Loftsson T. Masson M. Sigurdsson HH. [Related Articles, Links](#)


-  **Cyclodextrins and drug permeability through semi-permeable cellophane membranes.**
Int J Pharm. 2002 Jan 31;232(1-2):35-43.
PMID: 11790488 [PubMed - indexed for MEDLINE]


 **40:** Labella CR. Smith BW. Sigurdsson A. [Related Articles, Links](#)

-  **Effect of mouthguards on dental injuries and concussions in college basketball.**
Med Sci Sports Exerc. 2002 Jan;34(1):41-4.
PMID: 11782645 [PubMed - indexed for MEDLINE]


 **41:** Eldon BJ. Axelsson J. Sigurdsson SB. Arnason E. [Related Articles, Links](#)


-  **Cardiovascular risk factors and relatedness in an Icelandic subpopulation.**
Int J Circumpolar Health. 2001 Nov;60(4):499-502.
PMID: 11768425 [PubMed - indexed for MEDLINE]


 **42:** Sigurdsson S. Van Komen S. Bussen W. Schild D. Albala JS. Sung P. [Related Articles, Links](#)

-  **Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange.**
Genes Dev. 2001 Dec 15;15(24):3308-18.
PMID: 11751636 [PubMed - indexed for MEDLINE]


 **43:** Sigurdsson K. Adalsteinsson S. [Related Articles, Links](#)

-  **Risk variables affecting high-grade Pap smears at second visit: effects of screening interval, year, age and low-grade smears.**
Int J Cancer. 2001 Dec 15;94(6):884-8.
PMID: 11745493 [PubMed - indexed for MEDLINE]

 **44:** Di Lorenzo C. Youssef NN. Sigurdsson L. Scharff L. Griffiths J. Wald A. [Related Articles, Links](#)

-  **Visceral hyperalgesia in children with functional abdominal pain.**
J Pediatr. 2001 Dec;139(6):838-43.
PMID: 11743510 [PubMed - indexed for MEDLINE]

 **45:** Markley JC. Godde F. Sigurdsson ST. [Related Articles, Links](#)


-  **Identification and characterization of a divalent metal ion-dependent**

cleavage site in the hammerhead ribozyme.

Biochemistry. 2001 Nov 20;40(46):13849-56.


PMID: 11705374 [PubMed - indexed for MEDLINE]


-  **46:** [Sigurdsson TJ, Nguyen S, Wikesjö UM.](#) [Related Articles, Links](#)

 **Alveolar ridge augmentation with rhBMP-2 and bone-to-implant contact in induced bone.**

Int J Periodontics Restorative Dent. 2001 Oct;21(5):461-73.


PMID: 11693239 [PubMed - indexed for MEDLINE]


-  **47:** [Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V.](#) [Related Articles, Links](#)

 **The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men.**

Atherosclerosis. 2001 Nov;159(1):187-92.


PMID: 11689220 [PubMed - indexed for MEDLINE]


-  **48:** [Lee JY, Yanpiset K, Sigurdsson A, Vann WF Jr.](#) [Related Articles, Links](#)

 **Laser Doppler flowmetry for monitoring traumatized teeth.**

Dent Traumatol. 2001 Oct;17(5):231-5.


PMID: 11678544 [PubMed - indexed for MEDLINE]


-  **49:** [Flores MT, Andreasen JO, Bakland LK, Feiglin B, Gutmann JL, Oikarinen K, Pitt Ford TR, Sigurdsson A, Trope M, Vann WF Jr, Andreasen FM; International Association of Dental Traumatology.](#) [Related Articles, Links](#)

 **Guidelines for the evaluation and management of traumatic dental injuries.**

Dent Traumatol. 2001 Oct;17(5):193-8. No abstract available.


PMID: 11678536 [PubMed - indexed for MEDLINE]


-  **50:** [Sigurdsson V, Steegmans PH, van Vloten WA.](#) [Related Articles, Links](#)

 **The incidence of erythroderma: a survey among all dermatologists in The Netherlands.**

J Am Acad Dermatol. 2001 Nov;45(5):675-8.


PMID: 11606915 [PubMed - indexed for MEDLINE]


-  **51:** [Mohacsi P, Rieben R, Sigurdsson G, Tschanz H, Schaffner T, Nydegger UE, Carrel T.](#) [Related Articles, Links](#)

 **Successful management of a B-type cardiac allograft into an O-type man with 3(1/2)-year clinical follow-up.**

Transplantation. 2001 Oct 15;72(7):1328-30.


PMID: 11602865 [PubMed - indexed for MEDLINE]


-  **52:** [Loftsson T, Leeves N, Sigurjonsdottir JF, Sigurdsson HH, Masson M.](#) [Related Articles, Links](#)

 **Sustained drug delivery system based on a cationic polymer and an anionic drug/cyclodextrin complex.**

Pharmazie. 2001 Sep;56(9):746-7. No abstract available.


PMID: 11594000 [PubMed - indexed for MEDLINE]


-  **53:** [Mulder MM, Sigurdsson V, van Zuuren EJ, Klaassen EJ, Faber JA, de Wit JB, van Vloten WA.](#) [Related Articles, Links](#)


 **Psychosocial impact of acne vulgaris. evaluation of the relation between a change in clinical acne severity and psychosocial state.**

Dermatology. 2001;203(2):124-30.


PMID: 11586010 [PubMed - indexed for MEDLINE]


-  **54:** [Flores MT, Andreasen JO, Bakland LK, Feiglin B, Gutmann JL, Oikarinen K, Pitt Ford TR, Sigurdsson A, Trope M, Vann WF Jr, Andreasen FM; International Association of Dental Traumatology.](#) [Related Articles, Links](#)

-  **Guidelines for the evaluation and management of traumatic dental injuries.**
Dent Traumatol. 2001 Aug;17(4):145-8. No abstract available.
PMID: 11585138 [PubMed - indexed for MEDLINE]


 **55:** [Sigurdsson S, Stromberg R.](#)


[Related Articles](#), [Links](#)

-  **Evaluation of several economical computational methods for geometry optimization of phosphorus acid derivatives.**
Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1381-4.
PMID: 11563027 [PubMed - indexed for MEDLINE]


 **56:** [Markley JC, Chirakul P, Sologub D, Sigurdsson ST.](#)


[Related Articles](#), [Links](#)

-  **Incorporation of 2'-deoxy-5-(trifluoromethyl)uridine and 5-cyano-2'-deoxyuridine into DNA.**
Bioorg Med Chem Lett. 2001 Sep 17;11(18):2453-5.
PMID: 11549445 [PubMed - indexed for MEDLINE]


 **57:** [Sigurdsson BD, Thorgeirsson H, Linder S.](#)

[Related Articles](#), [Links](#)

-  **Growth and dry-matter partitioning of young Populus trichocarpa in response to carbon dioxide concentration and mineral nutrient availability.**
Tree Physiol. 2001 Aug;21(12-13):941-50.
PMID: 11498341 [PubMed - indexed for MEDLINE]

 **58:** [Gudjonsdottir M, Appendini L, Baderna P, Purro A, Patessio A, Vilianis G, Pastorelli M, Sigurdsson SB, Donner CF.](#)

[Related Articles](#), [Links](#)

-  **Diaphragm fatigue during exercise at high altitude: the role of hypoxia and workload.**
Eur Respir J. 2001 Apr;17(4):674-80.
PMID: 11401063 [PubMed - indexed for MEDLINE]

Display **Summary**  Show: **500**  **Sort**  **Send to** **Text** 


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: J Gen Virol. 1998 Apr;79 (Pt 4):937-45.

Related Articles, Links

FREE full text article at
vir.sgmjournals.org

Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants.

Harmeyer S, Pfaff E, Groschup MH.

Federal Research Centre for Virus Diseases of Animals, Tübingen, Germany.

Transmissible spongiform encephalopathies are closely linked to the accumulation of a pathological isoform of a host-encoded prion protein (PrP (C)), designated PrP(Sc). In an attempt to generate mono- and polyclonal antibodies to ruminant PrP, 32 mice were vaccinated with peptide vaccines which were synthesized according to the amino acid sequence of ovine PrP. By this approach five PrP-reactive polyclonal antisera directed against four different domains of the protein were stimulated. Splenocytes of mice which had developed PrP-reactive antibodies were used for the generation of monoclonal antibodies (MAbs). Obtained PrP-specific MAbs were directed to three different domains of ruminant PrP which differed from the three previously described major MAb binding sites in rodent PrP. MAbs exhibited reactivity with non-denatured ruminant PrP(C) in ELISA and immunoprecipitation and with denatured ovine and bovine PrP(Sc) in immunoblot. Cross-reactivity was observed with PrP(C) of nine other mammalian species and with pathological PrP preferably of ruminants and weakly with that of hamster and mouse. The generated MAbs will be useful tools for the development of diagnostic tests for BSE and scrapie as well as for pathogenesis studies of these diseases.

PMID: 9568991 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for AScr Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-72 of 72

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Jindra M, Gaziova I, Uhlirova M, Okabe M, Hiromi Y, Hirose S.](#) Related Articles, Links



Coactivator MBF1 preserves the redox-dependent AP-1 activity during oxidative stress in Drosophila.

EMBO J. 2004 Sep 1;23(17):3538-47. Epub 2004 Aug 12.

PMID: 15306851 [PubMed - in process]

☐ 2: [Mares JJ, Stavek J, Sestak J.](#) Related Articles, Links



Quantum aspects of self-organized periodic chemical reactions.

J Chem Phys. 2004 Jul 15;121(3):1499-503.

PMID: 15260695 [PubMed - in process]

☐ 3: [Perez Martinez A, Quintero Calcano V, Gonzalez Vicent M, Contra Gomez T, Diaz Perez MA, Madero Lopez L, Sevilla Navarro J.](#) Related Articles, Links



[High-dose chemotherapy with autologous stem cell rescue in children with high-risk and recurrent brain tumors]

An Pediatr (Barc). 2004 Jul;61(1):8-15. Spanish.

PMID: 15228928 [PubMed - in process]

☐ 4: [Tousova K, Susankova K, Teisinger J, Vyklicky L, Vlachova V.](#) Related Articles, Links



Oxidizing reagent copper-o-phenanthroline is an open channel blocker of the vanilloid receptor TRPV1.

Neuropharmacology. 2004 Aug;47(2):273-85.

PMID: 15223306 [PubMed - in process]

☐ 5: [Cejchan PA.](#) Related Articles, Links



LUCA, or just a conserved Archaeon?: comments on Xue et al.

Gene. 2004 May 26;333:47-50.

PMID: 15177679 [PubMed - in process]

☐ 6: [Cerna A, Cuadrado A, Jouve N, Diaz de la Espina SM, De la Torre C.](#) Related Articles, Links



Z-DNA, a new in situ marker for transcription.

Eur J Histochem. 2004;48(1):49-56.

PMID: 15145775 [PubMed - in process]

☐ 7: [Modak S, Gardner S, Dunkel LJ, Balmaceda C, Rosenblum MK, Miller DC, Halpern S, Finlay JL.](#) Related Articles, Links



Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.

J Clin Oncol. 2004 May 15;22(10):1934-43.

PMID: 15143087 [PubMed - indexed for MEDLINE]


☐ 8: [Gaziova I, Bonnette PC, Henrich VC, Jindra M.](#) Related Articles, Links




Cell-autonomous roles of the ecdysoneless gene in Drosophila development and oogenesis.


Development. 2004 Jun;131(11):2715-25. Epub 2004 May 05.

PMID: 15128659 [PubMed - indexed for MEDLINE]


 **9:** [Gardner SL](#).


[Related Articles](#), [Links](#)

 **Application of stem cell transplant for brain tumors.**
 Pediatr Transplant. 2004 Jun;8 Suppl 5:28-32.
 PMID: 15125703 [PubMed - in process]


 **10:** [Krusek J](#), [Dittert I](#), [Hendrych T](#), [Hnik P](#), [Horak M](#), [Petrovic M](#),
[Sedlacek M](#), [Susankova K](#), [Svobodova L](#), [Tousova K](#), [Ujec E](#),
[Vlachova V](#), [Vyklicky L](#), [Vyskocil F](#), [Vyklicky L Jr](#).


[Related Articles](#), [Links](#)

 **Activation and modulation of ligand-gated ion channels.**
 Physiol Res. 2004;53 Suppl 1:S103-13.
 PMID: 15119941 [PubMed - in process]


 **11:** [Frydrychova R](#), [Grossmann P](#), [Trubac P](#), [Vitkova M](#), [Marec F](#).


[Related Articles](#), [Links](#)

 **Phylogenetic distribution of TTAGG telomeric repeats in insects.**
 Genome. 2004 Feb;47(1):163-78.
 PMID: 15060613 [PubMed - indexed for MEDLINE]


 **12:** [Broniscer A](#), [Nicolaidis TP](#), [Dunkel IJ](#), [Gardner SL](#), [Johnson J Jr](#),
[Allen JC](#), [Sposto R](#), [Finlay JL](#).


[Related Articles](#), [Links](#)

 **High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.**
 Pediatr Blood Cancer. 2004 Mar;42(3):261-7.
 PMID: 14752864 [PubMed - indexed for MEDLINE]


 **13:** [Rego A](#), [Marec F](#).


[Related Articles](#), [Links](#)

 **Telomeric and interstitial telomeric sequences in holokinetic chromosomes of Lepidoptera: telomeric DNA mediates association between postpachytene bivalents in achiasmatic meiosis of females.**
 Chromosome Res. 2003;11(7):681-94.
 PMID: 14606630 [PubMed - indexed for MEDLINE]


 **14:** [Eguchi M](#), [Miyazaki T](#), [Masatsugu-Kato E](#), [Tsuzuki T](#), [Oribe T](#),
[Miwa N](#).


[Related Articles](#), [Links](#)

 **Cytoprotection against ischemia-induced DNA cleavages and cell injuries in the rat liver by pro-vitamin C via hydrolytic conversion into ascorbate.**
 Mol Cell Biochem. 2003 Oct;252(1-2):17-23.
 PMID: 14577572 [PubMed - indexed for MEDLINE]


 **15:** [Verma P](#), [Shah V](#), [Baldrian P](#), [Gabriel J](#), [Stopka P](#), [Trnka T](#), [Nerud F](#).

[Related Articles](#), [Links](#)


 **Decolorization of synthetic dyes using a copper complex with glucaric acid.**
 Chemosphere. 2004 Jan;54(3):291-5.
 PMID: 14575741 [PubMed - indexed for MEDLINE]


 **16:** [Adamova D](#), [Agakichiev G](#), [Appelshauser H](#), [Belaga V](#), [Braun-Munzinger P](#), [Cherlin A](#), [Damjanovic S](#), [Dietel T](#), [Dietrich L](#),
[Drees A](#), [Esumi SI](#), [Filimonov K](#), [Fomenko K](#), [Fraenkel Z](#),
[Garabatos C](#), [Glassel P](#), [Hering G](#), [Holeczek J](#), [Kushpil V](#), [Lenkeit B](#), [Maas A](#), [Marin A](#), [Milosevic J](#), [Milov A](#), [Miskowicz D](#),
[Panebrattsev Y](#), [Petchenova O](#), [Petracek V](#), [Pfeiffer A](#), [Rak J](#),
[Ravinovich I](#), [Rehak P](#), [Richter M](#), [Sako H](#), [Schmitz W](#), [Sedykh S](#),
[Seipp W](#), [Sharma A](#), [Shimansky S](#), [Slivova J](#), [Specht HJ](#), [Stachel J](#),
[Sumera M](#), [Tilsner H](#), [Tserruya I](#), [Wessels JP](#), [Wienold T](#),
[Windelband B](#), [Wurm JP](#), [Xie W](#), [Yurevich S](#), [Yurevich V](#),
[CERES/NA45 Collaboration](#).


[Related Articles](#), [Links](#)

 **Enhanced production of low-mass electron-positron pairs in 40-AGeV Pb-Au collisions at the CERN SPS.**
 Phys Rev Lett. 2003 Jul 25;91(4):042301. Epub 2003 Jul 22.
 PMID: 12906652 [PubMed]


 **17:** [Petrickova K, Petricek M.](#) Related Articles, Links


 **Eukaryotic-type protein kinases in *Streptomyces coelicolor*: variations on a common theme.**
Microbiology. 2003 Jul;149(Pt 7):1609-21. Review.
PMID: 12855714 [PubMed - indexed for MEDLINE]


 **18:** [Grunclova L, Fouquier H, Hypsa V, Kopacek P.](#) Related Articles, Links


 **Lysozyme from the gut of the soft tick *Ornithodoros moubata*: the sequence, phylogeny and post-feeding regulation.**
Dev Comp Immunol. 2003 Sep;27(8):651-60.
PMID: 12798362 [PubMed - indexed for MEDLINE]


 **19:** [Skrbek L, Gordeev AV, Soukup F.](#) Related Articles, Links

 **Decay of counterflow He II turbulence in a finite channel: possibility of missing links between classical and quantum turbulence.**
Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Apr;67(4 Pt 2):047302. Epub 2003 Apr 21.
PMID: 12786535 [PubMed]


 **20:** [Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenberg J, Martin PL.](#) Related Articles, Links

 **High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.**
J Clin Oncol. 2003 Jun 1;21(11):2187-91.
PMID: 12775745 [PubMed - indexed for MEDLINE]


 **21:** [Adamova D, Agakichiev G, Appelshauser H, Belaga V, Braun-Munzinger P, Castillo A, Cherlin A, Damjanovic S, Dietel T, Dietrich L, Drees A, Esumi SI, Filimonov K, Fomenko K, Fraenkel Z, Garabatos C, Glassel P, Hering G, Holeczek J, Kushpil V, Lenkeit B, Ludolphs W, Maas A, Marin A, Milosevic J, Milov A, Miskowicz D, Panebrattsev Y, Petchenova O, Petracek V, Pfeiffer A, Rak J, Ravinovich I, Rehak P, Sako H, Schmitz W, Schukraft J, Sedykh S, Shimansky S, Slivova J, Specht HJ, Stachel J, Sumera M, Tilsner H, Tserruya I, Wessels JP, Wienold T, Windeband B, Wurm JP, Xie W, Yurevich S, Yurevich V; CERES Collaboration](#) Related Articles, Links


 **Universal pion freeze-out in heavy-ion collisions.**
Phys Rev Lett. 2003 Jan 17;90(2):022301. Epub 2003 Jan 15.
PMID: 12570540 [PubMed]


 **22:** [Verma P, Baldrian P, Nerud F.](#) Related Articles, Links

 **Decolorization of structurally different synthetic dyes using cobalt (II)/ascorbic acid/hydrogen peroxide system.**
Chemosphere. 2003 Mar;50(8):975-9.
PMID: 12531702 [PubMed - indexed for MEDLINE]


 **23:** [Frydrychova R, Marec F.](#) Related Articles, Links

 **Repeated losses of TTAGG telomere repeats in evolution of beetles (Coleoptera).**
Genetica. 2002 Jun;115(2):179-87.
PMID: 12403172 [PubMed - indexed for MEDLINE]


 **24:** [Krasa J, Cejnarova A, Juha L, Ryc L, Scholz M, Kubes P.](#) Related Articles, Links


 **Semiconductor and thermoluminescent dosimetry of pulsed soft X ray plasma sources.**
Radiat Prot Dosimetry. 2002;100(1-4):429-32.
PMID: 12382914 [PubMed - indexed for MEDLINE]


 **25:** [Rihova B.](#) Related Articles, Links


 Immunomodulating activities of soluble synthetic polymer-bound drugs.
Adv Drug Deliv Rev. 2002 Sep 13;54(5):653-74. Review.
PMID: 12204597 [PubMed - indexed for MEDLINE]


 **26:** [Sastre A, Kavet R.](#) Related Articles, Links


 Candidate sites of action for microdosimetry associated with exposure to extremely-low-frequency magnetic fields, electric fields and contact currents.
Health Phys. 2002 Sep;83(3):387-94.
PMID: 12199552 [PubMed - indexed for MEDLINE]


 **27:** [Rolcik J, Lenobel R, Siglerova V, Strnad M.](#) Related Articles, Links

 Isolation of melatonin by immunoaffinity chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jul 25;775(1):9-15.
PMID: 12101055 [PubMed - indexed for MEDLINE]


 **28:** [St'astny M, Plocova D, Etrych T, Ulbrich K, Rihova B.](#) Related Articles, Links

 HPMa-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia.
Eur J Cancer. 2002 Mar;38(4):602-8.
PMID: 11872356 [PubMed - indexed for MEDLINE]


 **29:** [Sykova E, Fiala J, Antonova T, Vorisek I.](#) Related Articles, Links


 Extracellular space volume changes and diffusion barriers in rats with kaolin-induced and inherited hydrocephalus.
Eur J Pediatr Surg. 2001 Dec;11 Suppl 1:S34-7. No abstract available.
PMID: 11848042 [PubMed - indexed for MEDLINE]


 **30:** [Baldrian P, Gabriel J.](#) Related Articles, Links


 Copper and cadmium increase laccase activity in *Pleurotus ostreatus*.
FEMS Microbiol Lett. 2002 Jan 2;206(1):69-74.
PMID: 11786259 [PubMed - indexed for MEDLINE]


 **31:** [Jungwirth T, MacDonald AH.](#) Related Articles, Links


 Resistance spikes and domain wall loops in Ising quantum Hall ferromagnets.
Phys Rev Lett. 2001 Nov 19;87(21):216801. Epub 2001 Oct 30.
PMID: 11736361 [PubMed]


 **32:** [Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD.](#) Related Articles, Links

 Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9.
PMID: 11395243 [PubMed - indexed for MEDLINE]

 **33:** [Simon V, Vacik J, Michalek J, Novak V, Lopour P, Spunda M.](#) Related Articles, Links


 [Surgical treatment of recurrent urethral strictures in males after unsuccessful operations]
Cas Lek Cesk. 2000 Dec 6;139(24):767-71. Czech.
PMID: 11262915 [PubMed - indexed for MEDLINE]

 **34:** [Bendjelloul F, Rossmann P, Maly P, Mandys V, Jirkovska M, Prokesova L, Tuckova L, Tlaskalova-Hogenova H.](#) Related Articles, Links


 Detection of ICAM-1 in experimentally induced colitis of ICAM-1-deficient and wild-type mice: an immunohistochemical study.


Histochem J. 2000 Dec;32(12):703-9.
PMID: 11254085 [PubMed - indexed for MEDLINE]


 **35:** Kolacek J, Lipavsky P, Brandt EH. Related Articles, Links

 **Charge profile in vortices.**
Phys Rev Lett. 2001 Jan 8;86(2):312-5.
PMID: 11177819 [PubMed]


 **36:** Petrickova K, Tichy P, Petricek M. Related Articles, Links

 **Cloning and characterization of the pknA gene from Streptomyces coelicolor A3(2), coding for the Mn2+ dependent protein Ser/Thr kinase.**
Biochem Biophys Res Commun. 2000 Dec 29;279(3):942-8.
PMID: 11162454 [PubMed - indexed for MEDLINE]


 **37:** Dunkel JJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, Finlay JL, Abramson DH. Related Articles, Links

 **Successful treatment of metastatic retinoblastoma.**
Cancer. 2000 Nov 15;89(10):2117-21.
PMID: 11066053 [PubMed - indexed for MEDLINE]


 **38:** Tonka T, Weiser J. Related Articles, Links


 **Iridovirus infection in mayfly larvae.**
J Invertebr Pathol. 2000 Oct;76(3):229-31. No abstract available.
PMID: 11023753 [PubMed - indexed for MEDLINE]


 **39:** Yamada M. Related Articles, Links


 **Cerebral amyloid angiopathy: an overview.**
Neuropathology. 2000 Mar;20(1):8-22. Review.
PMID: 10935432 [PubMed - indexed for MEDLINE]


 **40:** Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Related Articles, Links


 **Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.**
Bone Marrow Transplant. 2000 Apr;25(8):885-94.
PMID: 10808211 [PubMed - indexed for MEDLINE]


 **41:** Havranek V, Kucera J, Horakova J, Vosecek V, Smolik J, Schwarz J, Sykorova I. Related Articles, Links


 **Matrix effects in PIXE analysis of aerosols and ashes.**
Biol Trace Elem Res. 1999 Winter;71-72:431-42.
PMID: 10676519 [PubMed - indexed for MEDLINE]


 **42:** Kucera J, Havranek V, Smolik J, Schwarz J, Vesely V, Kugler J, Sykorova I, Santroch J. Related Articles, Links

 **INAA and PIXE of atmospheric and combustion aerosols.**
Biol Trace Elem Res. 1999 Winter;71-72:233-45.
PMID: 10676497 [PubMed - indexed for MEDLINE]


 **43:** Abrey LE, Rosenblum MK, Papadopoulos E, Childs BH, Finlay JL. Related Articles, Links

 **High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors.**
J Neurooncol. 1999 Sep;44(2):147-53.
PMID: 10619498 [PubMed - indexed for MEDLINE]

 **44:** Bendjelloul F, Maly P, Mandys V, Jirkovska M, Prokesova L, Tuckova L, Tlaskalova-Hogenova H. Related Articles, Links

 **Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis.**
Clin Exp Immunol. 2000 Jan;119(1):57-63.

PMID: 10606964 [PubMed - indexed for MEDLINE]


-  **45:** [Tada T, Takizawa T, Nakazato F, Kobayashi S, Koike K, Oguchi M, Ishii E, Amano Y.](#) [Related Articles, Links](#)



Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.

J Neurooncol. 1999 Aug;44(1):71-6.

PMID: 10582672 [PubMed - indexed for MEDLINE]

-  **46:** [Grovas AC, Boyett JM, Lindsley K, Rosenblum M, Yates AJ, Finlay JL.](#) [Related Articles, Links](#)



Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepe, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.

Med Pediatr Oncol. 1999 Aug;33(2):83-7.

PMID: 10398181 [PubMed - indexed for MEDLINE]


-  **47:** [Subramanyan S, Kennedy MJ.](#) [Related Articles, Links](#)



Breast Cancer: High-Dose Therapy.

Oncologist. 1998;3(5):289-299.

PMID: 10388119 [PubMed - as supplied by publisher]


-  **48:** [Hann DM, Garovoy N, Finkelstein B, Jacobsen PB, Azzarello LM, Fields KK.](#) [Related Articles, Links](#)



Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study.

J Pain Symptom Manage. 1999 May;17(5):311-9.

PMID: 10355210 [PubMed - indexed for MEDLINE]


-  **49:** [Czyzewski EA, Goldman S, Mundt AJ, Nachman J, Rubin C, Hallahan DE.](#) [Related Articles, Links](#)



Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):569-77.

PMID: 10348286 [PubMed - indexed for MEDLINE]

-  **50:** [Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL, Dorsky D, Clive J, Mukherji B, Tutschka PJ.](#) [Related Articles, Links](#)



Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.

Bone Marrow Transplant. 1999 Mar;23(5):469-74.

PMID: 10100561 [PubMed - indexed for MEDLINE]

-  **51:** [Hou JW, Wang TR.](#) [Related Articles, Links](#)



Unusual features in children with inv dup(15) supernumerary marker: a study of genotype-phenotype correlation in Taiwan.

Eur J Pediatr. 1998 Feb;157(2):122-7.

PMID: 9504785 [PubMed - indexed for MEDLINE]

-  **52:** [Maurer K, Heitger A, Schwaighofer H, Fink FM, Niederweiser D.](#) [Related Articles, Links](#)



Double high-dose chemotherapy with autologous peripheral stem cell rescue in relapsed Wilms' tumor.

Bone Marrow Transplant. 1997 Dec;20(12):1111-3.

PMID: 9466289 [PubMed - indexed for MEDLINE]

-  **53:** [Zujewski J, Nelson A, Abrams J.](#) [Related Articles, Links](#)



Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer.

J Natl Cancer Inst. 1998 Feb 4;90(3):200-9. Review.

PMID: 9462677 [PubMed - indexed for MEDLINE]



54: [Dunkel JJ](#), [Boyett JM](#), [Yates A](#), [Rosenblum M](#), [Garvin JH Jr](#), [Bostrom BC](#), [Goldman S](#), [Sender LS](#), [Gardner SL](#), [Li H](#), [Allen JC](#), [Finlay JL](#).

[Related Articles](#), [Links](#)



High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group.

J Clin Oncol. 1998 Jan;16(1):222-8.

PMID: 9440746 [PubMed - indexed for MEDLINE]



55: [Kleiner S](#), [Kirsch A](#), [Schwaner I](#), [Kingreen D](#), [Schwella N](#), [Huhn D](#), [Siegert W](#).

[Related Articles](#), [Links](#)



High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.

Bone Marrow Transplant. 1997 Dec;20(11):953-9.

PMID: 9422474 [PubMed - indexed for MEDLINE]



56: [Ladenstein R](#), [Peters C](#), [Gadner H](#).

[Related Articles](#), [Links](#)



The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia.

Ann N Y Acad Sci. 1997 Sep 17;824:38-64. Review.

PMID: 9382454 [PubMed - indexed for MEDLINE]



57: [Meisenberg BR](#), [Miller WE](#), [McMillan R](#), [Callaghan M](#), [Sloan C](#), [Brehm T](#), [Kosty MP](#), [Kroener J](#), [Longmire R](#), [Saven A](#), [Piro LD](#).

[Related Articles](#), [Links](#)



Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies.

J Clin Oncol. 1997 Jan;15(1):11-7.

PMID: 8996119 [PubMed - indexed for MEDLINE]



58: [Beyer J](#), [Kingreen D](#), [Krause M](#), [Schleicher J](#), [Schwaner I](#), [Schwella N](#), [Huhn D](#), [Siegert W](#).

[Related Articles](#), [Links](#)



Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.

Cancer. 1997 Jan 1;79(1):161-8.

PMID: 8988741 [PubMed - indexed for MEDLINE]



59: [Brockstein BE](#), [Ross AA](#), [Moss TJ](#), [Kahn DG](#), [Hollingsworth K](#), [Williams SF](#).

[Related Articles](#), [Links](#)



Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.

J Hematother. 1996 Dec;5(6):617-24.

PMID: 9117250 [PubMed - indexed for MEDLINE]



60: [Pakandl M](#), [Eid Ahmed N](#), [Licois D](#), [Coudert P](#).

[Related Articles](#), [Links](#)



Eimeria magna Perard, 1925: study of the endogenous development of parental and precocious strains.

Vet Parasitol. 1996 Oct 25;65(3-4):213-22.

PMID: 8983147 [PubMed - indexed for MEDLINE]



61: [Siegert W](#), [Beyer J](#).

[Related Articles](#), [Links](#)



High-dose chemotherapy and ASCR of patients with relapsed or refractory germ cell tumors: long-term follow-up.

Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S60. No abstract available.
PMID: 8899176 [PubMed - indexed for MEDLINE]

-  **62:** [Meisenberg B, Gollard R, Brehm T, McMillan R, Miller W.](#) [Related Articles, Links](#)



Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.

Support Care Cancer. 1996 Sep;4(5):364-9.
PMID: 8883230 [PubMed - indexed for MEDLINE]

-  **63:** [Dunkel JJ, Finlay JL.](#) [Related Articles, Links](#)



High dose chemotherapy with autologous stem cell rescue for patients with medulloblastoma.

J Neurooncol. 1996 Jul;29(1):69-74. Review.
PMID: 8817417 [PubMed - indexed for MEDLINE]

-  **64:** [Hempel L, Kremens B, Weirich A, Graf N, Zintl F, Ludwig R.](#) [Related Articles, Links](#)



High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study.


Klin Padiatr. 1996 Jul-Aug;208(4):186-9.
PMID: 8776705 [PubMed - indexed for MEDLINE]

-  **65:** [Brockstein BE, Williams SF.](#) [Related Articles, Links](#)



High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow.


Stem Cells. 1996 Jan;14(1):79-89. Review.
PMID: 8820954 [PubMed - indexed for MEDLINE]

-  **66:** [Pakandl M, Gaca K, Drouet-viard F, Coudert P.](#) [Related Articles, Links](#)



Eimeria coecicola Cheissin 1947: endogenous development in gut-associated lymphoid tissue.

Parasitol Res. 1996;82(4):347-51.
PMID: 8740551 [PubMed - indexed for MEDLINE]

-  **67:** [Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE.](#) [Related Articles, Links](#)



Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.


J Clin Oncol. 1995 Feb;13(2):323-32.
PMID: 7844593 [PubMed - indexed for MEDLINE]

-  **68:** [Miksits K, Beyer J, Siegert W.](#) [Related Articles, Links](#)



Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue.


Bone Marrow Transplant. 1993 May;11(5):375-7.
PMID: 7684939 [PubMed - indexed for MEDLINE]

-  **69:** [Manzo J, Amodio-Groton MA, Kleinmann K.](#) [Related Articles, Links](#)



Antibiotic cost control measures in a hospital pharmacy.

Clin Ther. 1993;15 Suppl A:37-43.
PMID: 8513460 [PubMed - indexed for MEDLINE]


-  **70:** [Fields KK, Perkins JP, Hiemenz JW, Zorsky PE, Janssen WE, Kronish LE, Machak MC, Elfenbein GJ.](#) [Related Articles, Links](#)




Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.

Surg Oncol. 1993;2(1):87-95.
PMID: 7902764 [PubMed - indexed for MEDLINE]

☐ **71:** [Williams SF, Gilewski T, Mick R, Bitran JD.](#) [Related Articles, Links](#)

 **High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report.**
J Clin Oncol. 1992 Nov;10(11):1743-7.
PMID: 1357109 [PubMed - indexed for MEDLINE]

☐ **72:** [Williams SF, Mick R, Desser R, Golick J, Beschornier J, Bitran JD.](#) [Related Articles, Links](#)

 **High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.**
J Clin Oncol. 1989 Dec;7(12):1824-30.
PMID: 2511276 [PubMed - indexed for MEDLINE]

| | | | | | | |
|---------|---------|-------|-----|------|---------|------|
| Display | Summary | Show: | 500 | Sort | Send to | Text |
|---------|---------|-------|-----|------|---------|------|

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01

Connecting via winsock to STN
Welcome to STN International! Enter x:x
***** welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 17:03:28 ON 09 SEP 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 17:03:37 ON 09 SEP 2004

FILE 'AQUALINE' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:03:37 ON 09 SEP 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 17:03:37 ON 09 SEP 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 17:03:37 ON 09 SEP 2004

FILE 'CAPLUS' ENTERED AT 17:03:37 ON 09 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 17:03:37 ON 09 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 17:03:37 ON 09 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 17:03:37 ON 09 SEP 2004

FILE 'FOMAD' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 17:03:37 ON 09 SEP 2004

FILE 'HEALSAFE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 17:03:37 ON 09 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 17:03:37 ON 09 SEP 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 17:03:37 ON 09 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 17:03:37 ON 09 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 17:03:37 ON 09 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 17:03:37 ON 09 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 17:03:37 ON 09 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:37 ON 09 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 17:03:37 ON 09 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

=> S PrPsc OR AScr
34 FILES SEARCHED...
62 FILES SEARCHED...
L1 11834 PRPSC OR ASCR

=> S L1 AND adjuvant
49 FILES SEARCHED...
L2 108 L1 AND ADJUVANT

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3 76 DUP REM L2 (32 DUPLICATES REMOVED)

=> D L3 1-76

L3 ANSWER 1 OF 76 USPATFULL on STN DUPLICATE 1
AN 2004:18345 USPATFULL
TI Methods and compositions for treating a plaque-forming disease
IN Solomon, Beka, Herzlia Pitauch, ISRAEL
Frenkel, Dan, Rehovot, ISRAEL
PA Ramot at Tel-Aviv University Ltd., Tel-Aviv, ISRAEL (non-U.S. corporation)
PI US 2004013647 A1 20040122
AI US 2003-384788 A1 20030311 (10)
RLI Continuation-in-part of Ser. No. US 2001-808037, filed on 15 Mar 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-830954, filed on 7 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2002-162889, filed on 6 Jun 2002, PENDING Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-629971, filed on 31 Jul 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec 1999, ABANDONED A 371 of International Ser. No. WO 2000-IL518, filed on 31 Aug 2000, PENDING Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-629971, filed on 31 Jul 2000, ABANDONED Continuation of Ser. No. US 2000-629971, filed on 31 Jul 2000, ABANDONED
PRAI US 2002-371735P 20020412 (60)
US 1999-152417P 19990903 (60)
US 1999-152417P 19990903 (60)
DT Utility
FS APPLICATION
LN.CNT 4217
INCL INCLM: 424/093.200
INCLS: 514/044.000
NCL NCLM: 424/093.200
NCLS: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:473109 CAPLUS
DN 141:37595
TI M cell directed vaccines
IN Pascual, David w.
PA USA
SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Pat. Appl. 2004 33,486.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | US 2004109871 | A1 | 20040610 | US 2003-660787 | 20030912 |
| | WO 2001049867 | A1 | 20010712 | WO 2001-US426 | 20010108 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, | | | | |

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 WO 2002072015 A2 20020919 WO 2002-US7254 20020312
 WO 2002072015 A3 20021212
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004033486 A1 20040219 US 2002-169492 20021021
 PRAI US 2000-174786P P 20000106
 WO 2001-US426 W 20010108
 US 2001-274639P P 20010312
 WO 2002-US7254 A2 20020312
 US 2002-169492 A2 20021021

L3 ANSWER 3 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:141667 CAPLUS
 DN 140:198062
 TI Antigen arrays and compositions comprising antigenic determinant of RANKL
 protein and virus-like particle for treatment of bone disease and prion
 disease
 IN Bachmann, Martin; Maurer, Patrick; Spohn, Gunther
 PA Switz.
 SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of Appl. No. PCT/IB02/00166.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004033211 | A1 | 20040219 | US 2002-289456 | 20021107 |
| | US 2003175290 | A1 | 20030918 | US 2002-50902 | 20020118 |
| | WO 2002056905 | A2 | 20020725 | WO 2002-IB166 | 20020121 |
| | WO 2002056905 | A3 | 20031009 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 2001-331045P | P | 20011107 | | |
| | US 2002-50902 | A2 | 20020118 | | |
| | WO 2002-IB166 | A2 | 20020121 | | |
| | US 2002-396635P | P | 20020719 | | |
| | US 2001-262379P | P | 20010119 | | |
| | US 2001-288549P | P | 20010504 | | |
| | US 2001-326998P | P | 20011005 | | |

L3 ANSWER 4 OF 76 USPATFULL on STN
 AN 2004:171948 USPATFULL
 TI Method
 IN Enari, Masato, Chuo-ku, JAPAN
 Flechsig, Eckhard, Versbacher, GERMANY, FEDERAL REPUBLIC OF
 Collinge, John, Queen, UNITED KINGDOM
 Weismann, Charles, London, UNITED KINGDOM
 PI US 2004132109 A1 20040708
 AI US 2004-470022 A1 20040109 (10)
 WO 2002-GB257 20020122
 PRAI GB 2001-1762 20010123
 DT Utility
 FS APPLICATION
 LN.CNT 3141

INCL INCLM: 435/007.200
INCLS: 435/287.200
NCL NCLM: 435/007.200
NCLS: 435/287.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 76 USPATFULL on STN
AN 2004:94784 USPATFULL
TI ***prPsc*** -interacting molecules and uses thereof
IN Cashman, Neil, Toronto, CANADA
Paramithiotis, Eustache, Boucherville, CANADA
La Boissiere, Sylvie, Montreal, CANADA
Lawton, Robert, Gorham, ME, UNITED STATES
Francoeur, Greg, North Yarmouth, ME, UNITED STATES
Francoeur, Susan, Portland, ME, UNITED STATES LR
Estey, Lisa, Westbrook, ME, UNITED STATES
Pinard, Marc, Montreal, CANADA
PI US 2004072236 A1 20040415
AI US 2002-256538 A1 20020927 (10)
DT Utility
FS APPLICATION
LN.CNT 1436
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 76 USPATFULL on STN
AN 2004:69593 USPATFULL
TI Fusion proteins comprising DP-178 and other viral fusion inhibitor
peptides useful for treating aids
IN Bolognesi, Dani Paul, Durham, NC, UNITED STATES
Matthews, Thomas James, Durham, NC, UNITED STATES
Wild, Carl T., Durham, NC, UNITED STATES
Barney, Shawn O'apos, Lin, Cary, NC, UNITED STATES
Lambert, Dennis Michael, Cary, NC, UNITED STATES
Petteway, Stephen Robert, Cary, NC, UNITED STATES
Langlois, Alphonse J., Durham, NC, UNITED STATES
PA Duke University (U.S. corporation)
Trimeris, Inc. (U.S. corporation)
PI US 2004052820 A1 20040318
AI US 2002-267748 A1 20021008 (10)
RLI Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING
Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat.
No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed on
20 Dec 1994, GRANTED, Pat. No. US 6017536 Continuation-in-part of Ser.
No. US 1994-255208, filed on 7 Jun 1994, GRANTED, Pat. No. US 6440656
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993,
GRANTED, Pat. No. US 5464933
DT Utility
FS APPLICATION
LN.CNT 40442
INCL INCLM: 424/208.100
INCLS: 424/188.100; 530/350.000; 424/204.100; 530/300.000
NCL NCLM: 424/208.100
NCLS: 424/188.100; 530/350.000; 424/204.100; 530/300.000
IC [7]
ICM: A61K039-21
ICS: C07K014-16; A61K039-12; C07K002-00; C07K004-00; C07K005-00;
C07K007-00; C07K014-00; C07K016-00; C07K017-00; A61K038-00; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 76 USPATFULL on STN
AN 2004:69539 USPATFULL
TI Immunization against amyloid plaques using display technology
IN Solomon, Beka, Herzlia Pituach, ISRAEL
Frenkel, Dan, Rehovot, ISRAEL
PA Ramot at Tel-Aviv University, Ltd., Tel Aviv, ISRAEL (non-U.S.
corporation)
PI US 2004052766 A1 20040318
AI US 2003-618856 A1 20030715 (10)
RLI Continuation of Ser. No. US 1999-473653, filed on 29 Dec 1999, ABANDONED

PRAI US 1999-152417P 19990903 (60)
DT Utility
FS APPLICATION
LN.CNT 2570
INCL INCLM: 424/093.200
NCL NCLM: 424/093.200
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 76 USPATFULL on STN
AN 2004:44245 USPATFULL
TI Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides
useful for treating aids
IN Bolognesi, Dani Paul, Durham, NC, UNITED STATES
Matthews, Thomas James, Durham, NC, UNITED STATES
Wild, Carl T., Durham, NC, UNITED STATES
PA Duke University (U.S. corporation)
PI US 2004033235 A1 20040219
AI US 2003-267682 A1 20030106 (10)
RLI Continuation of Ser. No. US 1995-484223, filed on 7 Jun 1995, PENDING
Division of Ser. No. US 1995-470896, filed on 6 Jun 1995, GRANTED, Pat.
No. US 6479055 Continuation-in-part of Ser. No. US 1994-360107, filed on
20 Dec 1994, GRANTED, Pat. No. US 6017536 Continuation-in-part of Ser.
No. US 1994-255208, filed on 7 Jun 1994, GRANTED, Pat. No. US 6440656
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993,
GRANTED, Pat. No. US 5464933
DT Utility
FS APPLICATION
LN.CNT 59510
INCL INCLM: 424/186.100
INCLS: 424/188.100; 530/350.000; 424/208.100; 424/187.100
NCL NCLM: 424/186.100
NCLS: 424/188.100; 530/350.000; 424/208.100; 424/187.100
IC [7]
ICM: A61K039-21
ICS: A61K039-12; C07K014-16; C07K014-10; C07K014-05; C07K014-11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 76 USPATFULL on STN
AN 2004:181084 USPATFULL
TI Immunological detection of prions
IN Korth, Carsten, San Francisco, CA, United States
Stierli, Beat, Daenikon, SWITZERLAND
Stregt, Peter, Zurich, SWITZERLAND
Oesch, Bruno, Stilli, SWITZERLAND
Moser, Markus, Zurich, SWITZERLAND
PA Universitat Zurich, Zurich, SWITZERLAND (non-U.S. corporation)
PI US 6765088 B1 20040720
WO 9837210 19980827
AI US 1999-380015 19990823 (9)
WO 1998-EP917 19980218
PRAI DE 1997-102837 19970221
DT Utility
FS GRANTED
LN.CNT 1703
INCL INCLM: 530/388.100
INCLS: 424/139.100; 424/141.100; 435/007.100; 435/326.000; 435/331.000;
530/388.850
NCL NCLM: 530/388.100
NCLS: 424/139.100; 424/141.100; 435/007.100; 435/326.000; 435/331.000;
530/388.850
IC [7]
ICM: C07K016-00
EXF 435/7.1; 435/326; 435/331; 436/503; 436/518; 436/547; 530/387.1;
530/387.9; 530/388.1; 530/388.85; 800/4; 800/5; 800/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 76 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2004-501381 [48] WPIDS
DNN N2004-395892 DNC C2004-185869
TI Amplifying immunodetection of pathological prion protein, useful for
diagnosis of spongiform encephalopathy, by adding a macrocyclic
adjuvant ligand before reaction with antibody.
DC A26 A89 B04 D16 E19 S03
IN COLEMAN, A W; DA SILVA, E; MARTIN, A; MOUSSA, A; SHAHGALDIAN, P; DUPIN, M;

LAZAR, A N; LECLERE, E; PERRON, H
PA (FRSE-N) AGENCE FR SECURITE SANITAIRES ALIMENTS; (CNRS) CNRS CENT NAT RECH
SCI; (UYLY-N) UNIV LYON 1 BERNARD CLAUDE; (INMR) BIOMERIEUX SA
CYC 107
PI FR 2849205 A1 20040625 (200448)* 31 G01N033-68
WO 2004059322 A1 20040715 (200448) FR G01N033-68
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG
PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW
ADT FR 2849205 A1 FR 2002-16383 20021220; WO 2004059322 A1 WO 2003-FR3857
20031219
PRAI FR 2002-16383 20021220
IC ICM G01N033-68
ICS C12Q001-37; G01N033-566

L3 ANSWER 11 OF 76 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2004-27090 DRUGU T S
TI Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in
patients with recurrent or progressive CNS germ cell tumors.
AU Modak S; Gardner S; Dunkel I J; Balmaceda C; Rosenblum M K; Miller D C;
Halpern S; Finlay J L
CS Mem.Sloan-Kettering-Cancer-Cent.; Univ.New-York-Columbia; Univ.New-York
LO New York, N.Y., USA
SO J.Clin.Oncol. (22, No. 10, 1934-43, 2004) 3 Fig. 5 Tab. 40 Ref.
CODEN: JCONDN ISSN: 0732-183X
AV Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275
York Ave, New York, NY 10021, U.S.A. (e-mail: modaks@mskcc.org).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 12 OF 76 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 2
AN 2004:365298 BIOSIS
DN PREV200400368764
TI Multiple antigenic peptides facilitate generation of anti-prion
antibodies.
AU Bainbridge, J.; Jones, N.; Walker, B. [Reprint Author]
CS Dept Immunobiol, Natl Inst Biol Stand and Controls, Blanche Lane S Mimms,
Potters Bar, Herts, EN6 3QG, England
kbwalker@nibsc.ac.uk
SO Clinical and Experimental Immunology, (August 2004) Vol. 137, No. 2, pp.
298-304. print.
ISSN: 0009-9104 (ISSN print).
DT Article
LA English
ED Entered STN: 8 Sep 2004
Last Updated on STN: 8 Sep 2004

L3 ANSWER 13 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
AN 2003:930741 CAPLUS
DN 140:4064
TI vaccine comprising conjugates of prion protein and recombinant virus-like
particle carrier for treating prion diseases
IN Bachmann, Martin; Maurer, Patrik; Pelliccioli, Erica; Renner, Wolfgang A.
PA Cytos Biotechnology Ag, Switz.
SO U.S. Pat. Appl. Publ., 127 pp., Cont.-in-part of Appl. No. PCT/IB02/00166.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2003219459 | A1 | 20031127 | US 2003-346190 | 20030117 |
| | US 2003175290 | A1 | 20030918 | US 2002-50902 | 20020118 |
| | WO 2002056905 | A2 | 20020725 | WO 2002-IB166 | 20020121 |
| | WO 2002056905 | A3 | 20031009 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, | | | | |

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-50902 A2 20020118
WO 2002-IB166 A2 20020121
US 2002-393725P P 20020708
US 2002-396590P P 20020718
US 2001-262379P P 20010119
US 2001-288549P P 20010504
US 2001-326998P P 20011005
US 2001-331045P P 20011107

L3 ANSWER 14 OF 76 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 4

AN 10422134 IFIPAT;IFIUDB;IFICDB

TI SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES
HOMOLOGOUS TO AMYLOID BETA, PRION PROTEIN, AMYLIN, ALPHA-SYNUCLEIN, OR
POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO

IN Frangione Blas; Sigurdsson Einar M; Wisniewski Thomas

PA New York University (59449)

PI US 2003166558 A1 20030904

AI US 2002-301488 20021121

PRAI US 2001-331801P 20011121 (Provisional)

FI US 2003166558 20030904

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

CLMN 115

GI 15 Figure(s).

FIG. 1 shows the results of a thioflavin T fluorometric assay. Fibril formation of A beta 1-42, A beta 1-30-NH2, and K6A beta 1-30-NH2 (SEQ ID NO:6) was measured in vitro following incubation at 37 degrees C. K6A beta 1-30-NH2 was the only peptide that did not form fibrils at any of the time points.

FIGS. 2A and 2B show that A beta 40 and A beta 42 are toxic to human neuroblastoma cells (SK-N-SH) in culture as determined by the MTT assay, whereas K6A beta 30-NH2 has no effect at 2 days (FIG. 2A) and is slightly trophic at 6 days (FIG. 2B). *p less than 0.05; **p less than 0.01; ***p less than 0.001 compared to VEH group (one-way ANOVA).

FIGS. 3A-3D show coronal sections (X50; original magnification) stained with 6E10 against A beta, through the hippocampus and cortex in a Tg control-(FIG. 3A) and K6A beta 1-30-treated (FIG. 3B) Tg mouse. FIGS. 3C and 3D are adjacent sections (X100) double stained for interleukin-1 that recognizes microglia, and A beta. Note the reduction of amyloid burden in the immunized mouse (FIG. 3B), and the lack of ramified microglia (FIG. 3D) surrounding A beta plaque in the same mouse, compared to a control mouse (FIG. 3A, 3C). The bars in FIGS. 3A and 3C are 100 mu m. Abbreviations: hip=hippocampus; cx=cortex; cc=corpus callosum.

FIGS. 4A-4C show the reduction in cortical (FIG. 4A) and hippocampal (FIG. 4B) amyloid burden (6E10) following 7 months treatment with K6A beta 1-30-NH2. There is an 89% reduction in cortical amyloid burden (*p=0.0002; t-test; n=4 per group) and an 81% reduction in hippocampal amyloid burden (*p=0.0001). Soluble A beta 1-42 levels (FIG. 4C) are reduced by 57% within the brains of the vaccinated mice (*p=0.0019).

FIG. 5 shows the results of a thioflavin T fluorometric assay. Fibril formation of A beta 1-42, A beta 1-40, A beta 1-30-NH2, A beta 1-30K6, A beta 1-30-NH2 (EE18,19) and A beta 1-30-NH2 (DDL18,19) was measured in vitro following incubation at 37 degrees C. for 15 days. Within this period, no fibril formation of the A beta derivatives containing a polylysine segment or an amino acid substitution within the hydrophobic region was detected.

FIGS. 6A and 6B show the results of MTT cell toxicity assay. Neurotoxicity of A beta 1-42, A beta 1-40, A beta 1-30-NH2, K6A beta 1-30-NH2, A beta 1-30K6, A beta 1-30-NH2(EE,18,19) and A beta 1-30-NH2(DD,18,19) was determined following treatment of human neuroblastoma cells (SK-N-SH) for 2 (FIG. 6A) and 6 (FIG. 6B) days. *p less than 0.05; **p less than 0.01; ***p less than 0.001 compared to VEH group (one-way ANOVA). In this***

*** assay, A beta 1-40 and A beta 1-42 were toxic to human neuroblastoma***
*** cells (SK-N-SH) in culture. of the A beta derivatives, even at the***
*** highest concentration (100 mu M), only A beta 1-30K6 displayed a slight***
*** toxicity and only on day 2 of the test. Several of the peptides were***
*** neurotrophic following 6 days incubation. *p less than 0.05; **p***
*** less than 0.01; ***p less than 0.001 (One-way Anova; Neuman Keuls' posthoc***
*** test). ***

*** FIG. 7 shows the antibody titer determined by ELISA in mice 14 weeks after***
 *** vaccination with mouse recPrP. ***
 *** FIGS. 8A and 8B show that a higher anti-PrPC (ME7 FAS PrP) antibody titer***
 *** in vaccinated mice, as presented in FIG. 7, correlates with a longer***
 *** incubation time in both ***PrPSc*** inoculated mouse groups at lower
 dilution (FIG. 8A; $r^2=0.4389$, $p=0.0052$) and at higher dilution (FIG. 8B;
 $r^2=0.6786$, p less than 0.0001).
 FIG. 9 is a graph showing the effect of recPrP vaccination on disease
 onset, with day 0 being the first day an animal scored positive for
 disease. Group 1 mice were controls inoculated with ***PrPSc*** at a
 10 fold dilution, while group 2 was inoculated at the same dilution but
 also received recPrP vaccination. Group 3 mice were controls inoculated
 with ***PrPSc*** at a 1000 fold dilution, while Group 4 received the
 same dilution of ***PrPSc*** along with recPrP vaccination. The two
 control groups received ***adjuvant*** and vehicle injections. Two
 way ANOVA shows a significant effect for vaccination ($p=0.0005$) and
 PrPSc dilution (p less than 0.000001). The Newman-Keuls post-hoc
 test showed vaccination to have a stronger effect in the 10 fold dilution
 group (Group 1 versus 2, $p=0.001$ two-tailed; Group 3 versus 4, $p=0.036$
 one-tailed).
 FIG. 10 shows an alignment of amino acid sequences of prion protein (PrP)
 from human (SEQ ID NO:21), gorilla (SEQ ID NO:22), chimpanzee (SEQ ID
 NO:23), mouse (SEQ ID NO:24), rat (SEQ ID NO:25), Syrian hamster (SEQ ID
 NO:26), mink (SEQ ID NO:27), sheep (SEQ ID NO:28), goat (SEQ ID NO:29),
 cow (SEQ ID NO:30), and greater kudu (SEQ ID NO:31). Amino acid residues
 that are identical and conserved among the prion proteins of the species
 presented in this figure are boxed.
 FIGS. 11A-C show ELISA evaluation of sera from individual animals
 vaccinated with K6A beta 1-30-NH2 and alum ***adjuvant***, testing
 for antibody titer against antigen (FIG. 11A), A beta 142 (FIG. 11B) and
 A beta 1-40 (FIG. 11C).
 FIGS. 12A-C show ELISA evaluation of sera from individual animals
 immunized with A beta 1-42 and alum ***adjuvant***, testing for
 antibody titer against antigen (FIG. 12A), K6AP1-30-NH2 (FIG. 12B) and A
 beta 1-40 (FIG. 12C).
 FIGS. 13A and 13B depict a linear maze used to evaluate cognitive
 capabilities of animals vaccinated with A beta 1-30NH2 and K6A beta
 1-30-NH2 together with alum ***adjuvants***, as well as controls.
 FIG. 13A shows the maze design during the adaptation phase, and FIG. 13B
 during testing. Dotted lines indicate blocked alleys.
 FIGS. 14A-C depict results obtained from behavioral studies of animals of
 about 3-4 months of age, after vaccination with A beta 1-30-NH2 and K6A
 beta 1-30-NH2 together with alum ***adjuvants***, as well as
 controls. The studies included testing of locomotor activity (FIG. 14A),
 spontaneous avoidance (FIG. 14B), and passive avoidance (FIG. 14C). See
 Example 6.
 FIGS. 15A-N depict results obtained from behavioral studies of animals of
 about 11 months of age, after vaccination with A beta 1-30-NH2 and K6A
 beta 1-30-NH2 together with alum ***adjuvants***, as well as
 controls. The studies included testing of locomotor activity (FIG. 15A),
 and cognitive testing using traverse beam (FIGS. 15B and 15C), rotarod
 (FIG. 15D), radial arm maze (FIGS. 15E and 15F), straight alley channel
 (FIG. 15G), visible platform (FIGS. 15H and 15I), Morris water maze
 (FIGS. 15J and 15K), probe trial (FIGS. 15L and 15M), and linear maze
 (FIG. 15N). See Example 6.

L3 ANSWER 15 OF 76 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 5
 AN 10304838 IFIPAT;IFIUDB;IFICDB
 TI AGENT; THERAPY, PREVENTION PRION INFECTIONS; USING MONOCLONAL ANTIBODIES
 ENCAPSULATED AS HYBRIDOMAS
 IN Enari Masato (JP); Weissmann Charles (GB)
 PA Unassigned Or Assigned To Individual (68000)
 PI US 2003049249 A1 20030313
 AI US 2001-985164 20011101
 PRAI GB 2001-221621 20010913
 FI US 2003049249 20030313
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 OS CA 138:231762
 CLMN 8
 GI 4 Figure(s).

FIG. 1 represents the susceptibility to scrapie infection and PrP level of
 various sublines of N2a cells. N2a populations as propagated routinely in
 the lab and single clones transformed with a PrP expression or a control
 vector are seeded into 24well plates (2 x 10⁴ cells/well) and grown to

confluence. (a) Cultures are exposed for 3 days to purified mouse ***PrPSc*** (RML strain, 20 ng/ml), cultured for 29 days (8 passages) and assayed for ***PrPSc*** formation by the cell blot assay. (b) Prionsusceptible N2a/Bos2 and resistant N2a/2M11 cells are exposed for 3 days to the dilutions indicated of infected 10% brain homogenate, cultured for 14 days (3 passages) and assayed for ***PrPSc*** formation. Cells exposed to a 10⁻⁴ dilution are still slightly positive (c) Western blot analysis of N2a sublines is performed using monoclonal anti-PrP antibody 6H4. Cells transfected with the expression plasmid for mouse PrPc, MHM2 PrP or MH2M PrP are indicated by mo, M2 or 2M, respectively. BOS designates cells cotransfected with pSVneo and pEF-BOS-EX. N2a, the original uncloned cells, as well as the highly susceptible N2a/Bos2 cell line show similar, low expression of PrPC as compared to the non-susceptible moS or 2M11 lines.

FIG. 2 represents anti PrP antibody 6H4 and PIPLC preventing infection of N2a/Bos2 cell with scrapie prions and abrogate ***PrPSc*** accumulation in chronically infected cells. (a) N2a/Bos2 cells are incubated for 2 h with antibody 6H4 or PIPLC at the concentrations indicated and exposed to 0.1% scrapie-infected brain homogenate (fmal concentration) for 3 days. After culturing for 14 days (3 passages) in the absence of PIPLC or in the continued presence of 6H4, ***PrPSc*** expression is determined. (b,c) Chronically scrapie-infected N2a/Bos2 cells are cultured for (b) 3 days at the levels of antibody 6H4 or of PIPLC indicated or (c) 14 days (3 passages) at the concentrations of antibody 6H4 indicated, and ***PrPSc*** accumulation is monitored. (d) Chronically scrapie-infected N2a/Bos2 cells are exposed to 6H4 at the concentrations indicated for 2 weeks and further cultured in the absence of the antibody for 6 weeks. Cultures are split 1:5 every 34 days. There is no reappearance of ***PrPSc***. "Cell staining" refers to staining of the membranes with ethidium bromide to monitor efficiency of transfer of the cell layer. IN, chronically scrapie-infected N2a/Bos2 cells.

FIG. 3 represents chronically infected N2a/Bos2 cells "cured" of ***PrPSc*** by antibody 6H4 treatment continuing to produce PrP and their susceptibility to reinfection. (a) Chronically infected N2a/Bos2 cells, treated with antibody 6H4 for 2 weeks at the concentrations indicated and propagated in its absence for 66 days were not exposed (top 2 rows) or exposed to 0.1% RMLinfected mouse brain homogenate for 3 days (bottom 2 rows). After culturing for 14 days, ***PrPSc*** is monitored by the cell blot assay. (b) Relative susceptibility to prions of N2a/Bos2 cells (BOS2) and N2a/Bos2 cells "cured" by exposure to antibody 6H4 at 20 µg/ml is determined by exposing cultures to various dilutions of RML-infected mouse brain homogenate for 3 days and determining ***PrPSc*** as above. (c) Levels of PrPC and ***PrPSc*** in various sublines are determined by Western blotting. Chronically infected N2a/Bos2 cells, treated for 2 weeks with antibody 6H4 at the concentrations indicated are passaged for 84 days after antibody withdrawal. Cells are lysed and samples corresponding to 2.25 x 10⁵ cells are incubated in the presence (+PK) or absence (-PK) of proteinase K (5 µg/ml) for 90 minutes at 37 degrees C. Western blotting is performed as described in Methods. UN, uninfected N2a/Bos2 cells and I-BOS2, chronically prion-infected BOS2 cells. Molecular weight markers are indicated at the left of each panel.

FIG. 4 represents a model to explain abolition of ***PrPSc*** by anti PrP antibody (or PIPLC). PrPC is attached to the membrane by a glycosylphosphatidyl inositol anchor and cycles between the cell surface and an endocytic compartment (43). In scrapieinfected cells, PrPC is recruited into ***PrPSc*** "seeds" (44), which may be located at the cell surface and/or in the endocytic/lysosomal compartment. ***PrPSc*** is degraded with a halflife of about 15 h (37); if PrPC is prevented from converting to ***PrPSc*** by either a blocking antibody or by being stripped from the cell surface by PIPLC, ***PrPSc*** will diminish and ultimately disappear.

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------|--|------|----------|-----------------|----------|
| PI | WO 2004000351 | A1 | 20031231 | WO 2003-EP6541 | 20030620 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ | | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US | 2004005338 | A1 | 20040108 | US 2003-465811 | 20030620 |
| PRAI | US 2002-389898P | P | 20020620 | | |
| RE.CNT | 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L3 ANSWER 17 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:590953 CAPLUS
DN 139:128014
TI Methods for treating diseases or conditions with peptide constructs
IN Zimmerman, Daniel H.; Charoenvit, Yupin; Rosenthal, Kenneth S.; Whelan, Mike
PA Cel-Sci Corporation, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2003061589 | A2 | 20030731 | WO 2003-US1816 | 20030123 |
| | WO 2003061589 | A3 | 20040527 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 2002-349982P | P | 20020123 | | |
| | US 2002-349983P | P | 20020123 | | |
| | US 2002-350032P | P | 20020123 | | |

L3 ANSWER 18 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:570846 CAPLUS
DN 139:132445
TI Pharmaccine comprising conjugates of prion protein and virus-like particle carrier for treating prion diseases
IN Bachmann, Martin; Maurer, Patrick; Pelliccioli, Erica; Renner, Wolfgang A.
PA Cytos Biotechnology A.-G., Switz.
SO PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 9

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | WO 2003059386 | A2 | 20030724 | WO 2003-EP460 | 20030117 |
| | WO 2003059386 | A3 | 20040311 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW | | | | |

ML, MR, NE, SN, TD, TG

| | | | | |
|---------------|----|----------|---------------|----------|
| US 2003175290 | A1 | 20030918 | US 2002-50902 | 20020118 |
| WO 2002056905 | A2 | 20020725 | WO 2002-IB166 | 20020121 |
| WO 2002056905 | A3 | 20031009 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-50902 A 20020118
 WO 2002-IB166 A 20020121
 US 2002-393725P P 20020708
 US 2002-396590P P 20020718
 US 2001-262379P P 20010119
 US 2001-288549P P 20010504
 US 2001-326998P P 20011005
 US 2001-331045P P 20011107

L3 ANSWER 19 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:434266 CAPLUS
 DN 139:21013

TI Synthetic immunogenic/non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response
 IN Frangione, Blas; Wisniewski, Thomas; Sigurdsson, Einar M.
 PA New York University, USA
 SO PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003045128 | A2 | 20030605 | WO 2002-US37634 | 20021121 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003166558 | A1 | 20030904 | US 2002-301488 | 20021121 |
| PRAI | US 2001-331801P | P | 20011121 | | |

L3 ANSWER 20 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:334937 CAPLUS
 DN 138:349696

TI Fusion protein comprising cytokines, chemokines, and interferons for use as vaccine ***adjuvant*** in immunotherapy for cancer and viral infection
 IN Galipeau, Jacques; Stagg, John
 PA Centre for Translational Research In Cancer, Can.
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2003035105 | A2 | 20030501 | WO 2002-CA1649 | 20021023 |
| | WO 2003035105 | A3 | 20030918 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, | | | | |

RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 EP 1440090 A2 20040728 EP 2002-769821 20021023
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 PRAI US 2001-330476P P 20011023
 WO 2002-CA1649 W 20021023

L3 ANSWER 21 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:242184 CAPLUS
 DN 138:285995

TI Packaging of immunostimulatory substances and antigens into virus-like
 particles for use as vaccines against cancer, autoimmune disease, allergy
 and viral infection

IN Maurer, Patrick; Tissot, Alain; Schwarz, Katrin; Meijerink, Edwin;
 Lipowsky, Gerad; Pumpens, Paul; Cielens, Indulis; Renhofa, Regina;
 Bachmann, Martin F.; Storni, Tazio

PA Cytos Biotechnology A.-G., Switz.

SO PCT Int. Appl., 322 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2003024481 | A2 | 20030327 | WO 2002-IB4132 | 20020916 |
| | WO 2003024481 | A3 | 20040603 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2003099668 | A1 | 20030529 | US 2002-244065 | 20020916 |
| | EP 1450856 | A2 | 20040901 | EP 2002-777600 | 20020916 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | |
| PRAI | US 2001-318994P | P | 20010914 | | |
| | US 2002-374145P | P | 20020422 | | |
| | WO 2002-IB4132 | W | 20020916 | | |

L3 ANSWER 22 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:242183 CAPLUS
 DN 138:270293

TI Vaccine compositions comprising anti-CD4 antibody or immunostimulatory
 nucleic acid and antigen-coupled virus-like particles for enhancement of
 immune responses

IN Bachmann, Martin F.; Storni, Tazio; Lechner, Franziska

PA Cytos Biotechnology A.-G., Switz.

SO PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2003024480 | A2 | 20030327 | WO 2002-IB4252 | 20020916 |
| | WO 2003024480 | A3 | 20031030 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, | | | |

NE, SN, TD, TG
US 2003091593 A1 20030515 US 2002-243739 20020916
EP 1425040 A2 20040609 EP 2002-783338 20020916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRAI US 2001-318967P P 20010914
WO 2002-IB4252 W 20020916

L3 ANSWER 23 OF 76 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10454587 IFIPAT;IFIUDB;IFICDB
TI FRAGMENTS OF PRION PROTEINS
IN Fishleigh Robert Vincent (GB); Mee Roger Paul (GB); Robson Barry (GB)
PA Proteus Molecular Design Ltd GB (43521)
PI US 2003199013 A1 20031023
AI US 2002-116061 20020405
RLI WO 1992-GB2246 19921203 Section 371 PCT Filing UNKNOWN
US 1994-244701 19940602 DIVISION 5773572
US 1998-76721 19980513 DIVISION 6379905
PRAI GB 1991-257477 19911203
GB 1992-146638 19920710
FI US 2003199013 20031023
US 5773572
US 6379905
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 45

L3 ANSWER 24 OF 76 USPATFULL on STN
AN 2003:334947 USPATFULL
TI Nucleotide sequences that code for torsin genes, torsin proteins, and
methods of using the same to treat protein-aggregation
IN Caldwell, Guy A., Tuscaloosa, AL, UNITED STATES
Caldwell, Kim A., Tuscaloosa, AL, UNITED STATES
PA THE UNIVERSITY OF ALABAMA, Tuscaloosa, AL (U.S. corporation)
PI US 2003235823 A1 20031225
AI US 2002-177104 A1 20020624 (10)
DT Utility
FS APPLICATION
LN.CNT 3296
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500; 514/012.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500; 514/012.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C12P021-02; C12N005-06; C07K014-47; C07K016-20;
A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 76 USPATFULL on STN
AN 2003:330543 USPATFULL
TI Immunological methods and compositions for the treatment of Alzheimer's
disease
IN St. George-Hyslop, Peter H., Toronto, CANADA
McLaurin, JoAnne, Toronto, CANADA
PA Hospital for Sick Children and University of Toronto (non-U.S.
corporation)
PI US 2003232758 A1 20031218
AI US 2003-411544 A1 20030410 (10)
PRAI US 2002-373914P 20020419 (60)
DT Utility
FS APPLICATION
LN.CNT 2487
INCL INCLM: 514/012.000
INCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 514/012.000
NCLS: 530/324.000; 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: A61K038-17
ICS: C07K014-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 76 USPATFULL on STN

AN 2003:324329 USPATFULL
TI Antibodies specific for native ***PrPsc***
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Williamson, R. Anthony, San Diego, CA, UNITED STATES
Burton, Dennis R., LaJolla, CA, UNITED STATES
PA The Regents of the University of California and The Scripps Research
Institute (U.S. corporation)
PI US 2003228303 A1 20031211
AI US 2003-435602 A1 20030509 (10)
RLI Continuation of Ser. No. US 2001-943906, filed on 30 Aug 2001, GRANTED,
Pat. No. US 6562341 Continuation of Ser. No. US 2000-550374, filed on 13
Apr 2000, GRANTED, Pat. No. US 6372214 Continuation of Ser. No. US
1998-36579, filed on 6 Mar 1998, GRANTED, Pat. No. US 6290954 Division
of Ser. No. US 1996-713939, filed on 13 Sep 1996, GRANTED, Pat. No. US
5846533 Continuation-in-part of Ser. No. US 1995-528104, filed on 14 Sep
1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2983
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 76 USPATFULL on STN
AN 2003:264865 USPATFULL
TI Therapy for human cancers using cisplatin and other drugs or genes
encapsulated into liposomes
IN Boulikas, Teni, Palo Alto, CA, UNITED STATES
PI US 2003185879 A1 20031002
AI US 2003-350470 A1 20030123 (10)
RLI Division of Ser. No. US 1999-434345, filed on 5 Nov 1999, GRANTED, Pat.
No. US 6511676
DT Utility
FS APPLICATION
LN.CNT 1652
INCL INCLM: 424/450.000
INCL: 424/649.000
NCL NCLM: 424/450.000
NCL: 424/649.000
IC [7]
ICM: A61K009-127
ICS: A61K033-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 76 USPATFULL on STN
AN 2003:264794 USPATFULL
TI Prostate cell lines
IN Thraves, Peter, London, UNITED KINGDOM
Sutton, Andrew, London, UNITED KINGDOM
PI US 2003185808 A1 20031002
AI US 2002-240523 A1 20021023 (10)
WO 2001-GB1437 20010330
PRAI GB 2000-8032 20000401
GB 2000-24237 20001003
DT Utility
FS APPLICATION
LN.CNT 727
INCL INCLM: 424/093.210
INCL: 514/044.000; 435/366.000; 424/085.200
NCL NCLM: 424/093.210
NCL: 514/044.000; 435/366.000; 424/085.200
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 76 USPATFULL on STN
AN 2003:206867 USPATFULL
TI Antibodies specific for ungulate PrP
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Safar, Jiri G., Walnut Creek, CA, UNITED STATES
Williamson, R. Anthony, San Diego, CA, UNITED STATES
Burton, Dennis R., La Jolla, CA, UNITED STATES
PI US 2003143224 A1 20030731

AI US 2003-355780 A1 20030130 (10)
RLI Continuation of Ser. No. US 2000-627218, filed on 27 Jul 2000, GRANTED,
Pat. No. US 6537548
DT Utility
FS APPLICATION
LN.CNT 2123
INCL INCLM: 424/130.100
INCLS: 435/345.000; 435/006.000
NCL NCLM: 424/130.100
NCLS: 435/345.000; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: A61K039-395; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 76 USPATFULL on STN
AN 2003:181684 USPATFULL
TI Surface simulation synthetic peptides useful in the treatment of
hyper-variable viral pathogens
IN Crevecœur, Harry F., Valley Stream, NY, UNITED STATES
PI US 2003125518 A1 20030703
AI US 2001-12806 A1 20011201 (10)
DT Utility
FS APPLICATION
LN.CNT 1650
INCL INCLM: 530/327.000
INCLS: 530/328.000; 435/005.000; 702/019.000
NCL NCLM: 530/327.000
NCLS: 530/328.000; 435/005.000; 702/019.000
IC [7]
ICM: C07K007-08
ICS: C12Q001-70; G01N033-48; G06F019-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 76 USPATFULL on STN
AN 2003:126727 USPATFULL
TI Novel methods for down-regulation of amyloid
IN Jensen, Martin Roland, Horsholm, DENMARK
Birk, Peter, Horsholm, DENMARK
Nielsen, Klaus Gregorius, Horsholm, DENMARK
PI US 2003086938 A1 20030508
AI US 2002-204362 A1 20020816 (10)
WO 2001-DK113 20010219
PRAI DK 2000-265 20000221
DT Utility
FS APPLICATION
LN.CNT 3114
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 76 USPATFULL on STN
AN 2003:112522 USPATFULL
TI Agents and compositions and methods utilizing same useful in diagnosing
and/or treating or preventing plaque forming
IN Solomon, Beka, Herzlia Pituach, ISRAEL
Hanan, Eilat, Tel Aviv, ISRAEL
Frenkel, Dan, Rehovot, ISRAEL
PA Ramot University Authority for Applied Research & Industrial
Development, Tel Aviv, ISRAEL (non-U.S. corporation)
PI US 2003077252 A1 20030424
AI US 2002-162889 A1 20020606 (10)
RLI Continuation of Ser. No. US 2000-629971, filed on 31 Jul 2000, ABANDONED
Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec 1999,
PENDING
PRAI US 1999-152417P 19990903 (60)
DT Utility
FS APPLICATION
LN.CNT 2994
INCL INCLM: 424/093.200
INCLS: 514/044.000; 435/456.000; 435/235.100
NCL NCLM: 424/093.200
NCLS: 514/044.000; 435/456.000; 435/235.100
IC [7]

ICM: A61K048-00

ICS: C12N007-01; C12N015-86

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 76 USPATFULL on STN
AN 2003:44722 USPATFULL
TI Early pre-symptomatic prion diagnostic blood test for encephalopathies
IN Resink, Annelies, Paris, FRANCE
Fuentes, Nathalie, Kremlin Bicetre, FRANCE
Schweighoffer, Fabien, Vincennes, FRANCE
PI US 2003032032 A1 20030213
AI US 2002-100178 A1 20020319 (10)
PRAI US 2001-278670P 20010321 (60)
US 2001-282463P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 962
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 76 USPATFULL on STN
AN 2003:273427 USPATFULL
TI Inhibitors of amyloid formation
IN Caughey, Winslow S., Hamilton, MT, United States
Caughey, Byron, Hamilton, MT, United States
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 6632808 B1 20031014
WO 2000009111 20000224
AI US 2001-762725 20010307 (9)
WO 1999-US18297 19990811
PRAI US 1998-96148P 19980811 (60)
DT Utility
FS GRANTED
LN.CNT 1503
INCL INCLM: 514/185.000
INCLS: 514/410.000; 540/122.000; 540/145.000
NCL NCLM: 514/185.000
NCLS: 514/410.000; 540/122.000; 540/145.000
IC [7]
ICM: A61K031-409
ICS: C07D487-22
EXF 514/185; 514/410; 540/122; 540/145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 76 USPATFULL on STN
AN 2003:81453 USPATFULL
TI Antibodies specific for ungulate PrP
IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri, Concord, CA, United States
Williamson, R. Anthony, San Diego, CA, United States
Burton, Dennis R., La Jolla, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
The Scripps Research Institute, La Jolla, CA, United States (U.S.
corporation)
PI US 6537548 B1 20030325
AI US 2000-627218 20000727 (9)
DT Utility
FS GRANTED
LN.CNT 2073
INCL INCLM: 424/130.100
INCLS: 424/009.100; 424/185.100; 435/007.100; 435/070.100; 435/071.100;
530/387.100; 530/398.100
NCL NCLM: 424/130.100
NCLS: 424/009.100; 424/185.100; 435/007.100; 435/070.100; 435/071.100;
530/387.100; 530/389.100
IC [7]
ICM: A61K039-395
EXF 424/9.1; 424/130.1; 424/185.1; 435/7.1; 435/70.1; 435/71.1; 436/503;
436/547; 530/387.1; 530/388.27; 530/398.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 76 USPATFULL on STN
AN 2003:40533 USPATFULL
TI Methods for the inhibition of epstein-barr virus transmission employing
anti-viral peptides capable of abrogating viral fusion and transmission
IN Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6518013 B1 20030211
AI US 1995-485546 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994,
now patented, Pat. No. US 6017536 Continuation-in-part of Ser. No. US
1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US
1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
FS GRANTED
LN.CNT 24700
INCL INCLM: 435/005.000
INCLS: 424/230.100; 530/300.000; 530/324.000; 530/325.000; 530/326.000
NCL NCLM: 435/005.000
NCLS: 424/230.100; 530/300.000; 530/324.000; 530/325.000; 530/326.000
IC [7]
ICM: C12Q001-70
EXF 435/5; 530/300; 530/324-329; 530/350; 424/230.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 76 USPATFULL on STN
AN 2003:26157 USPATFULL
TI Therapy for human cancers using cisplatin and other drugs or genes
encapsulated into liposomes
IN Boulikas, Teni, 249 Matadero Ave., Palo Alto, CA, United States 94306
PI US 6511676 B1 20030128
AI US 1999-434345 19991105 (9)
DT Utility
FS GRANTED
LN.CNT 1642
INCL INCLM: 424/450.000
INCLS: 264/004.100; 264/004.300
NCL NCLM: 424/450.000
NCLS: 264/004.100; 264/004.300
IC [7]
ICM: A61K009-127
EXF 424/450; 264/4.1; 264/4.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 76 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2004-07769 DRUGU P
TI Immunotherapy as a therapeutic treatment for neurodegenerative disorders.
AU White A R; Hawke S H
CS Howard-Florey-Inst.; Univ.London
LO Melbourne, Austr.; London, U.K.
SO J.Neurochem. (87, No. 4, 801-08, 2003) 1 Fig. 56 Ref.
CODEN: JONRA9 ISSN: 0022-3042
AV Neurochemistry Group, Howard Florey Institute of Experimental Physiology
and Medicine, Victoria 3010, Australia. (e-mail:
a.white@hfi.unimelb.edu.au).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 39 OF 76 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 6
AN 2003:86974 BIOSIS
DN PREV200300086974
TI Complete Freund's ****adjuvant**** immunization prolongs survival in
experimental prion disease in mice.
AU Tal, Yuval; Souan, Lina; Cohen, Irun R. [Reprint Author]; Meiner, Zeev;
Taraboulos, Albert; Mor, Felix
CS Department of Immunology, Weizmann Institute of Science, P.O. Box 26,
Rehovot, 76100, Israel
irun.cohen@weizmann.ac.il
SO Journal of Neuroscience Research, (January 15 2003) Vol. 71, No. 2, pp.
286-290. print.
ISSN: 0360-4012 (ISSN print).
DT Article

LA English
ED Entered STN: 6 Feb 2003
Last Updated on STN: 6 Feb 2003

L3 ANSWER 40 OF 76 MEDLINE on STN
AN 2003475318 MEDLINE
DN PubMed ID: 14550926
TI Immunisation with a synthetic prion protein-derived peptide prolongs
AU survival times of mice orally exposed to the scrapie agent.
Schwarz Anja; Kratke Oliver; Burwinkel Michael; Riemer Constanze; Schultz
CS Julia; Henklein Peter; Bamme Theresa; Baier Michael
SO Project Neurodegenerative Diseases, Robert-Koch-Institute, Nordufer 20,
13353 Berlin, Germany.
Neuroscience letters, (2003 Oct 30) 350 (3) 187-9.
CY Journal code: 7600130. ISSN: 0304-3940.
OT Ireland
LA Journal; Article; (JOURNAL ARTICLE)
ES English
EM Priority Journals
ED 200311
Entered STN: 20031011
Last Updated on STN: 20031111
Entered Medline: 20031110

L3 ANSWER 41 OF 76 USPATFULL on STN DUPLICATE 7
AN 2002:272456 USPATFULL
TI Antibodies specific for native ***PrPSc***
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Williamson, R. Anthony, San Diego, CA, UNITED STATES
PI Burton, Dennis R., La Jolla, CA, UNITED STATES
US 2002150571 A1 20021017
US 6562341 B2 20030513
AI US 2001-943906 A1 20010830 (9)
RLI Continuation of Ser. No. US 2000-550374, filed on 13 Apr 2000, PENDING
Continuation of Ser. No. US 1998-36579, filed on 6 Mar 1998, PATENTED
Division of Ser. No. US 1996-713939, filed on 13 Sep 1996, PATENTED
Continuation-in-part of Ser. No. US 1995-528104, filed on 14 Sep 1995,
ABANDONED
OT Utility
ES APPLICATION
LN.CNT 2374
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
NCLS: 424/009.100; 424/009.200; 424/147.100; 435/007.100; 435/070.100;
435/071.100; 436/503.000; 436/518.000; 436/547.000; 530/387.100
[7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 76 USPATFULL on STN DUPLICATE 8
AN 2002:259529 USPATFULL
TI Discordant helix stabilization for prevention of amyloid formation
IN Johansson, Jan, Stockholm, SWEDEN
PI US 2002143105 A1 20021003
US 6716589 B2 20040406
AI US 2001-988842 A1 20011119 (9)
PRAI US 2000-253695P 20001120 (60)
US 2000-251662P 20001206 (60)
OT Utility
ES APPLICATION
LN.CNT 1541
INCL INCLM: 525/054.100
NCL NCLM: 435/007.200
[7]
ICM: C08H001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:185399 CAPLUS
DN 136:229029
TI Method for precipitating mono and multiple layers of organophosphoric and
organophosphonic acids and the salts thereof in addition to use thereof
N Hofer, Rolf; Pawlak, Michael; Textor, Marcus; Schuermann-Mader, Eveline;
A Ehrat, Markus; Tosatti, Samuele
O Zeptosens A.-G., Switz.
PCT Int. Appl., 88 pp.

CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002020873 | A2 | 20020314 | WO 2001-EP10077 | 20010831 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001089859 | A5 | 20020322 | AU 2001-89859 | 20010831 |
| | EP 1315968 | A2 | 20030604 | EP 2001-969680 | 20010831 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2003186914 | A1 | 20031002 | US 2003-363555 | 20030305 |
| PRAI | CH 2000-1732 | A | 20000905 | | |
| | WO 2001-EP10077 | W | 20010831 | | |
| OS | MARPAT 136:229029 | | | | |

L3 ANSWER 44 OF 76 USPATFULL on STN
AN 2002:329478 USPATFULL
TI Novel method for down-regulation of amyloid
IN Jensen, Martin Roland, Holte, DENMARK
Rasmussen, Peter Birk, Frederiksberg, DENMARK
Nielsen, Klaus Gregorius, Soborg, DENMARK

PI US 2002187157 A1 20021212
AI US 2001-785215 A1 20010220 (9)
PRAI PA 2000-200000265 20000221
US 2000-186295P 20000301 (60)

DT Utility
FS APPLICATION
LN.CNT 3272

INCL INCLM: 424/185.100
INCLS: 424/085.100; 424/085.200
NCL NCLM: 424/185.100
NCLS: 424/085.100; 424/085.200

IC [7]
ICM: A61K039-00
ICS: A61K038-19; A61K038-20

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 76 USPATFULL on STN
AN 2002:251957 USPATFULL
TI Conformational and topological protein regulation
IN Lingappa, Vishwanath R., San Francisco, CA, UNITED STATES
Rutkowski, D. Thomas, San Francisco, CO, UNITED STATES
Hegde, Ramanugan S., Rockville, MD, UNITED STATES

PI US 2002137915 A1 20020926
AI US 2000-739179 A1 20001215 (9)
PRAI US 1999-171012P 19991215 (60)
US 1999-172350P 19991216 (60)

DT Utility
FS APPLICATION
LN.CNT 3036

INCL INCLM: 536/023.500
INCLS: 435/007.210; 435/006.000; 435/325.000; 435/070.210; 435/326.000
NCL NCLM: 536/023.500
NCLS: 435/007.210; 435/006.000; 435/325.000; 435/070.210; 435/326.000

IC [7]
ICM: C12Q001-68
ICS: G01N033-567; C07H021-04; C12P021-04; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 76 USPATFULL on STN
AN 2002:178549 USPATFULL
TI Vaccine for the prevention and treatment of alzheimer's and amyloid
IN Chalifour, Robert, Ile Bizard, CANADA
Hebert, Lise, Brossard, CANADA
Kong, Xianqi, Dollard-des-Oremaux, CANADA

Gervais, Francine, Ile Bizard, CANADA
PI US 2002094335 A1 20020718
AI US 2001-867847 A1 20010529 (9)
RLI Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000,
PENDING
PRAI US 1999-168594P 19991129 (60)
DT Utility
FS APPLICATION
LN.CNT 1946
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 76 USPATFULL on STN
AN 2002:99410 USPATFULL
TI Methods and compositions for the treatment and/or diagnosis of
neurological diseases and disorders
IN Solomon, Beka, Herzlia Pituach, ISRAEL
Frenkel, Dan, Rehovot, ISRAEL
PI US 2002052311 A1 20020502
AI US 2001-808037 A1 20010315 (9)
RLI Continuation-in-part of Ser. No. US 2000-629971, filed on 31 Jul 2000,
PENDING Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec
1999, PENDING
PRAI US 1999-152417P 19990903 (60)
DT Utility
FS APPLICATION
LN.CNT 4074
INCL INCLM: 514/002.000
INCL INCLM: 424/093.210
NCL NCLM: 514/002.000
NCL NCLM: 424/093.210
IC [7]
ICM: A61K048-00
ICS: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 48 OF 76 USPATFULL on STN
AN 2002:72861 USPATFULL
TI Pharmaceutical compositions comprising a soluble laminin receptor
precursor or a compound which blocks the interaction of the laminin
receptor precursor and ***PrPSc*** or PrPc
IN Weiss, Stefan, Munich, GERMANY, FEDERAL REPUBLIC OF
PI US 2002040001 A1 20020404
AI US 2001-964566 A1 20010928 (9)
RLI Continuation-in-part of Ser. No. US 2000-424754, filed on 13 Apr 2000,
PENDING
PRAI EP 1997-108712 19970530
WO 1998-EP3220 19980529
DT Utility
FS APPLICATION
LN.CNT 2050
INCL INCLM: 514/012.000
INCL INCLM: 435/007.100
NCL NCLM: 514/012.000
NCL NCLM: 435/007.100
IC [7]
ICM: A61K038-17
ICS: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 49 OF 76 USPATFULL on STN
AN 2002:297296 USPATFULL
TI Methods for inhibition of membrane fusion-associated events, including
respiratory syncytial virus transmission
IN Bolognesi, Dani Paul, Durham, NC, United States
Matthews, Thomas James, Durham, NC, United States
Wild, Carl T., Durham, NC, United States
Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
Langlois, Alphonse J., Durham, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6479055 B1 20021112

AI US 1995-470896 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994,
now patented, Pat. No. US 6017536 Continuation-in-part of Ser. No. US
1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US
1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DT Utility
FS GRANTED
LN.CNT 26553
INCL INCLM: 424/211.100
INCLS: 424/186.100; 530/324.000
NCL NCLM: 424/211.100
NCLS: 424/186.100; 530/324.000
IC [7]
ICM: A61K039-145
EXF 435/5; 435/240.2; 424/184.1-189.1; 424/204.1-211.1; 424/225.1;
424/227.1; 424/230.1; 514/1; 514/2; 530/324; 530/350; 530/826
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 50 OF 76 USPATFULL on STN
AN 2002:81024 USPATFULL
TI Antibodies specific for native ***PrPSc***
IN Prusiner, Stanley B., San Francisco, CA, United States
Williamson, R. Anthony, San Diego, CA, United States
Burton, Dennis R., La Jolla, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
The Scripps Research Institute, La Jolla, CA, United States (U.S.
corporation)
PI US 6372214 B1 20020416
AI US 2000-550374 20000413 (9)
RLI Continuation of Ser. No. US 1998-36579, filed on 6 Mar 1998 Division of
Ser. No. US 1996-713939, filed on 13 Sep 1996, now patented, Pat. No. US
5846533, issued on 8 Dec 1998 Continuation-in-part of Ser. No. US
1995-528104, filed on 14 Sep 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 2518
INCL INCLM: 424/130.100
INCLS: 424/009.100; 424/147.100; 435/007.100; 435/070.100; 435/071.100;
436/503.000; 436/518.000; 436/547.000; 530/387.100
NCL NCLM: 424/130.100
NCLS: 424/009.100; 424/147.100; 435/007.100; 435/070.100; 435/071.100;
436/503.000; 436/518.000; 436/547.000; 530/387.100
IC [7]
ICM: A61K039-395
ICS: C12P019-00; G01N033-567; G01N033-543; C07K016-00
EXF 424/9.1; 424/130.1; 424/147.1; 435/7.1; 435/70.1; 435/71.1; 530/387.1;
436/518; 436/503; 436/547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 51 OF 76 USPATFULL on STN
AN 2002:51103 USPATFULL
TI Methods and compositions for the manufacture of halogenated
anthracyclines with increased antitumor activity, other anthracyclines,
halogenated sugars, and glycosyl donors
IN Priebe, Waldemar, 4239 Emory St., Houston, TX, United States 77005
Krawczyk, Marta, 175 N. Locust Hill Dr. apt. #2308, Lexington, KY,
United States 40503
Skibicki, Piotr, Waszyngton Street 39 Apartment 24, Warsaw 04015, POLAND
Fokt, Izabela, 1908 Nursery Rd., The Woodlands, TX, United States 77380
Dziewiszek, Krzysztof, 1908 Nursery Rd., The Woodlands, TX, United
States 77380
Gryniewicz, Grzegorz, .mu.. Zielona 16B/2, 05-092 Lomianki, POLAND
Perez-Soler, Roman, 564 1st Ave. #20T, New York, NY, United States
10016
PI US 6355784 B1 20020312
AI US 1999-330226 19990610 (9)
PRAI US 1998-89162P 19980612 (60)
DT Utility
FS GRANTED
LN.CNT 2062
INCL INCLM: 536/006.400
INCLS: 536/004.100; 536/017.200; 536/018.400; 536/018.700; 536/122.000
NCL NCLM: 536/006.400
NCLS: 536/004.100; 536/017.200; 536/018.400; 536/018.700; 536/122.000
IC [7]

ICM: C07H015-24
EXF 536/6.4; 536/18.6; 536/122; 536/18.4; 536/18.7; 536/4.1; 536/17.2;
514/34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 52 OF 76 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2002:986508 SCISEARCH
GA The Genuine Article (R) Number: 620PU
TI Induction of antibodies against murine full-length prion protein in
wild-type mice
AU Koller M F; Grau T; Christen P (Reprint)
CS Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland
(Reprint); Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland
CYA Switzerland
SO JOURNAL OF NEUROIMMUNOLOGY, (NOV 2002) Vol. 132, No. 1-2, pp. 113-116.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS.
ISSN: 0165-5728.
DT Article; Journal
LA English
REC Reference Count: 17
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 53 OF 76 USPATFULL on STN DUPLICATE 9
AN 2001:224147 USPATFULL
TI Prevention of cancer
IN Henrik, Raskov Hans, Hellerup, Denmark
PI US 2001049364 A1 20011206
US 6703380 B2 20040309
AI US 2001-825891 A1 20010405 (9)
RLI Continuation-in-part of Ser. No. WO 2000-DK546, filed on 29 Sep 2000,
UNKNOWN
PRAI DK 1999-1390 19990929
DT Utility
FS APPLICATION
LN.CNT 1937
INCL INCLM: 514/164.000
INCLS: 514/167.000
NCL NCLM: 514/165.000
NCLS: 514/167.000
IC [7]
ICM: A61K031-616
ICS: A61K031-59

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 54 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:816487 CAPLUS
DN 135:356752
TI Epitope synchronization in antigen presenting cells
IN Simard, John J. L.; Diamond, David C.; Lei, Xiang-Dong
PA CTL Immunotherapies Corp., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|--|----------|-----------------|----------|
| PI WO 2001082963 | A2 | 20011108 | WO 2001-US13806 | 20010427 |
| WO 2001082963 | A3 | 20020411 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| EP 1276896 | A2 | 20030122 | EP 2001-930922 | 20010427 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| JP 2003535824 | T2 | 20031202 | JP 2001-579836 | 20010427 |
| PRAI US 2000-560465 | A | 20000428 | | |

US 2000-561074 A 20000428
US 2000-561571 A 20000428
US 2000-561572 A 20000428
WO 2001-US13806 W 20010427

L3 ANSWER 55 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:507867 CAPLUS
DN 135:91527
TI Tissue-specific DNA delivery via M cell-directed vaccines, and enhanced in
vivo mucosal IgA and T cell responses resulting therefrom
IN Pascual, David W.
PA Research and Development Institute, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------|---|------|----------|-----------------|----------|
| PI | WO 2001049867 | A1 | 20010712 | WO 2001-US426 | 20010108 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1257654 | A1 | 20021120 | EP 2001-901811 | 20010108 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2004033486 | A1 | 20040219 | US 2002-169492 | 20021021 |
| | US 2004109871 | A1 | 20040610 | US 2003-660787 | 20030912 |
| PRAI | US 2000-174786P | P | 20000106 | | |
| | WO 2001-US426 | W | 20010108 | | |
| | US 2001-274639P | P | 20010312 | | |
| | WO 2002-US7254 | A2 | 20020312 | | |
| | US 2002-169492 | A2 | 20021021 | | |
| RE.CNT 7 | THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L3 ANSWER 56 OF 76 USPATFULL on STN
AN 2001:157792 USPATFULL
TI Antibodies specific for native ****PrPSc****
IN Prusiner, Stanley B., San Francisco, CA, United States
Williamson, R. Anthony, San Diego, CA, United States
Burton, Dennis R., La Jolla, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6290954 B1 20010918
AI US 1998-36579 19980306 (9)
RLI Division of Ser. No. US 1996-713939, filed on 13 Sep 1996, now patented, Pat. No. US 5846533 Continuation-in-part of Ser. No. US 1995-528104, filed on 14 Sep 1995, now abandoned
DT Utility
FS GRANTED
LN.CNT 2513
INCL INCLM: 424/130.100
INCLS: 424/009.100; 424/147.100; 435/007.100; 435/070.100; 435/071.100; 436/503.000; 436/518.000; 436/547.000; 530/387.100
NCL NCLM: 424/130.100
NCLS: 424/009.100; 424/147.100; 435/007.100; 435/070.100; 435/071.100; 436/503.000; 436/518.000; 436/547.000; 530/387.100
IC [7]
ICM: A61K039-395
ICS: G01N033-53; G01N033-567; C07K016-00
EXF 424/9.1; 424/130.1; 424/147.1; 435/7.1; 435/70.1; 435/71.1; 530/387.1; 436/518; 436/503; 436/547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 57 OF 76 USPATFULL on STN
AN 2001:125727 USPATFULL
TI Correction of genetic defects using chemical chaperones
IN Welch, William J., San Francisco, CA, United States
Brown, C. Randell, Hershey, PA, United States

PA Tatzelt, Jorg, Munchen, Germany, Federal Republic of
The Regents of The University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6270954 B1 20010807
AI US 1999-291406 19990413 (9)
RLI Continuation-in-part of Ser. No. US 1997-838691, filed on 9 Apr 1997,
now patented, Pat. No. US 5900360
PRAI US 1996-15155P 19960410 (60)
DT Utility
FS GRANTED
LN.CNT 2342
INCL INCLM: 435/004.000
INCLS: 435/026.000; 435/023.000; 435/024.000; 435/963.000
NCL NCLM: 435/004.000
NCLS: 435/023.000; 435/024.000; 435/026.000; 435/963.000
IC [7]
ICM: C12Q001-00
ICS: C12Q001-32; C12Q001-37
EXF 435/4; 435/26; 435/23; 435/24; 435/963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 58 OF 76 USPATFULL on STN
AN 2001:67794 USPATFULL
TI Human respiratory syncytial virus peptides with antifusogenic and
antiviral activities
IN Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)
PI US 6228983 B1 20010508
AI US 1995-485264 19950607 (8)
RLI Division of Ser. No. US 1995-470896, filed on 6 Jun 1995
Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994
Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994
Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now
patented, Pat. No. US 5464933
DT Utility
FS Granted
LN.CNT 32166
INCL INCLM: 530/300.000
INCLS: 530/324.000; 530/325.000; 530/326.000; 424/211.100; 424/186.100
NCL NCLM: 530/300.000
NCLS: 424/186.100; 424/211.100; 530/324.000; 530/325.000; 530/326.000
IC [7]
ICM: A61K038-00
EXF 530/350; 530/324-329; 530/300; 424/211.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 59 OF 76 USPATFULL on STN
AN 2001:51590 USPATFULL
TI Clearance and inhibition of conformationally altered proteins
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael, San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6214366 B1 20010410
AI US 1999-322903 19990601 (9)
DT Utility
FS Granted
LN.CNT 1037
INCL INCLM: 424/405.000
INCLS: 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 424/078.320;
424/078.350; 424/078.360; 424/078.370; 424/078.380; 514/772.300;
514/772.400; 514/772.500; 514/772.600; 514/772.700
NCL NCLM: 424/405.000
NCLS: 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380;
424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 514/772.300;
514/772.400; 514/772.500; 514/772.600; 514/772.700
IC [7]
ICM: A01N025-10
EXF 424/78.32; 424/78.35; 424/78.38; 424/405; 424/438; 424/442; 424/DIG.16;
514/772.3-772.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 60 OF 76 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2002-049350 [06] WPIDS
 DNN N2002-036483 DNC C2002-013896
 TI New polypeptides, useful as antiviral agents, comprise their prion proteins able to bind nucleic acid, nucleocapsid proteins, and ligands for use as antiprion agents.
 DC B04 C06 D16 S03
 IN DARLIX, J L; GABUS, D C; LEBLANC, P; DARLIX, J; GABUS-DARLIX, C
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE
 CYC 95
 PI WO 2001083747 A2 20011108 (200206)* FR 80 C12N015-12
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
 SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 FR 2808278 A1 20011102 (200206) C07K014-435
 AU 2001056454 A 20011112 (200222) C12N015-12
 ADT WO 2001083747 A2 WO 2001-FR1336 20010430; FR 2808278 A1 FR 2000-5535
 20000428; AU 2001056454 A AU 2001-56454 20010430
 FDT AU 2001056454 A Based on WO 2001083747
 PRAI FR 2000-5535 20000428
 IC ICM C07K014-435; C12N015-12
 ICS A61K038-17; A61K039-395; A61K048-00; A61P025-00; A61P031-12;
 C07K014-47; C07K019-00; C12N007-00; C12N015-86; C12Q001-68;
 C12Q001-70; G01N033-569; G01N033-68

 L3 ANSWER 61 OF 76 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 10
 AN 2001435095 EMBASE
 TI Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and
 moxifloxacin.
 AU Garcia-Saenz M.C.; Arias-Puente A.; Fresnadillo-Martinez M.J.;
 Carrasco-Font C.
 CS Dr. M.C. Garcia-Saenz, Fundacion Hospital de Alcorcon, Budapest 1, 28922
 Alcorcon, Madrid, Spain. mcgarcias@fhhalcorcon.es
 SO Journal of Cataract and Refractive Surgery, (2001) 27/12 (1969-1974).
 Refs: 23
 ISSN: 0886-3350 CODEN: JCSUEV
 PUI S 0886-3350(01)00997-X
 CY United States
 DT Journal; Article
 FS 012 Ophthalmology
 037 Drug Literature Index
 LA English
 SL English

 L3 ANSWER 62 OF 76 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003330992 EMBASE
 TI Short-term effect of mitomycin-C augmented trabeculectomy on axial length
 and corneal astigmatism.
 AU Kook M.S.; Kim H.B.; Lee S.U.
 CS Dr. M.S. Kook, Department of Ophthalmology, Ulsan University School of
 Medicine, Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul,
 138-736, Korea, Republic of
 SO Journal of Cataract and Refractive Surgery, (2001) 27/4 (518-523).
 Refs: 25
 ISSN: 0886-3350 CODEN: JCSUEV
 PUI S 0886-3350(00)00646-5
 CY United States
 DT Journal; Article
 FS 012 Ophthalmology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English

 L3 ANSWER 63 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:861780 CAPLUS
 DN 134:28436
 TI Vaccines against conformation-dependent protein and non-protein antigens
 IN Goletz, Steffen; Karsten, Uwe
 PA Max-Delbrück-Centrum fuer Molekulare Medizin, Germany
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|--|----------|------------------|----------|
| PI | WO 2000073430 | A2 | 20001207 | WO 2000-DE1809 | 20000529 |
| | WO 2000073430 | A3 | 20010329 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | DE 10027695 | A1 | 20010419 | DE 2000-10027695 | 20000529 |
| | EP 1181058 | A2 | 20020227 | EP 2000-951201 | 20000529 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| PRAI | DE 1999-19924405 | A | 19990527 | | |
| | DE 1999-19943016 | A | 19990909 | | |
| | WO 2000-DE1809 | W | 20000529 | | |

L3 ANSWER 64 OF 76 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:529259 CAPLUS
DN 133:132106
TI Prion gene knockout animal cell lines, antiviral vaccine production, and mutant prion gene detection in mammals
IN Yokoyama, Takashi; Itoharu, Shigemitsu; Onodera, Takashi
PA Ministry of Agriculture, Forestry and Fisheries National Institute of Animal, Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | JP 2000210078 | A2 | 20000802 | JP 1999-13834 | 19990122 |
| | JP 3084399 | B2 | 20000904 | | |
| PRAI | JP 1999-13834 | | 19990122 | | |

L3 ANSWER 65 OF 76 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2001-070921 [08] WPIDS
CR 2004-411388 [38]
DNC C2001-019767
TI Pharmaceutical composition comprising immunogen against amyloid component such as fibril peptide or protein, or antibody against amyloid component useful for treating amyloid diseases or amyloidoses.

DC B04 D16 P31
IN SCHENK, D B; MASLIAH, E
PA (NEUR-N) NEURALAB LTD; (MASL-I) MASLIAH E; (SCHE-I) SCHENK D B
CYC 94

| | | | | | |
|----|---------------|--|--------------------|--------|------------|
| PI | WO 2000072876 | A2 | 20001207 (200108)* | EN 140 | A61K039-00 |
| | RW: | AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW | | | |
| | W: | AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US VZ VN YU ZA ZW | | | |
| | AU 2000053163 | A | 20001218 (200118) | | |
| | NO 2001005758 | A | 20020130 (200223) | | A61K000-00 |
| | EP 1185296 | A2 | 20020313 (200225) | EN | A61K039-00 |
| | R: | AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI | | | |
| | BR 2000011103 | A | 20020319 (200228) | | A61K039-00 |
| | HU 2002001205 | A2 | 20020828 (200264) | | A61K039-00 |
| | KR 2002025884 | A | 20020404 (200266) | | A61K038-00 |
| | SK 2001001718 | A3 | 20020910 (200274) | | A61K039-00 |
| | CZ 2001004154 | A3 | 20021113 (200282) | | A61K039-00 |
| | CN 1377278 | A | 20021030 (200314) | | A61K039-00 |
| | JP 2003516929 | W | 20030520 (200334) | 166 | A61K045-08 |
| | ZA 2001009662 | A | 20030730 (200355) | 155 | A61K000-00 |
| | MX 2001012293 | A1 | 20021201 (200377) | | A61K039-00 |
| | US 2004146521 | A1 | 20040729 (200450) | | A61K039-00 |

ADT WO 2000072876 A2 WO 2000-US15239 20000601; AU 2000053163 A AU 2000-53163
20000601; NO 2001005758 A WO 2000-US15239 20000601, NO 2001-5758 20011126;
EP 1185296 A2 EP 2000-938075 20000601, WO 2000-US15239 20000601; BR
2000011103 A BR 2000-11103 20000601, WO 2000-US15239 20000601; HU
2002001205 A2 WO 2000-US15239 20000601, HU 2002-1205 20000601; KR
2002025884 A KR 2001-715508 20011201; SK 2001001718 A3 WO 2000-US15239
20000601, SK 2001-1718 20000601; CZ 2001004154 A3 WO 2000-US15239
20000601, CZ 2001-4154 20000601; CN 1377278 A CN 2000-808358 20000601; JP
2003516929 W WO 2000-US15239 20000601, JP 2001-511318 20000601; ZA
2001009662 A ZA 2001-9662 20011123; MX 2001012293 A1 WO 2000-US15239
20000601, MX 2001-12293 20011129; US 2004146521 A1 Provisional US
1999-137010P 19990601, CIP of US 2000-580015 20000526, CIP of US
2000-585817 20000601, Provisional US 2002-423012P 20021101, US 2003-698099
20031031

FDT AU 2000053163 A Based on WO 2000072876; EP 1185296 A2 Based on WO
2000072876; BR 2000011103 A Based on WO 2000072876; HU 2002001205 A2 Based
on WO 2000072876; SK 2001001718 A3 Based on WO 2000072876; CZ 2001004154
A3 Based on WO 2000072876; JP 2003516929 W Based on WO 2000072876; MX
2001012293 A1 Based on WO 2000072876

PRAI US 1999-137010P 19990601; US 2000-580015 20000526;
US 2000-585817 20000601; US 2002-423012P 20021101;
US 2003-698099 20031031

IC ICM A61K000-00; A61K038-00; A61K039-00; A61K045-08
ICS A61K039-385; A61K039-39; A61K039-395; A61K039-44; A61K047-48;
A61K048-00; A61P001-04; A61P003-00; A61P017-00; A61P017-06;
A61P019-00; A61P019-02; A61P025-28; A61P029-00; A61P035-00;
A61P037-00; A61P043-00; G01N033-68

ICA C12N015-09

L3 ANSWER 66 OF 76 Elsevier BIOBASE COPYRIGHT 2004 Elsevier science B.V.
on STN DUPLICATE

AN 2000253205 ES BIOBASE

TI Successful treatment of metastatic retinoblastoma

AU Dunkel I.J.; Aledo A.; Kernan N.A.; Kushner B.; Bayer L.; Gollamudi S.V.;
Finlay J.L.; Abramson D.H.

CS Dr. I.J. Dunkel, Department of Pediatrics, Mem. Sloan-Kettering Cancer
Center, Box 185, 1275 York Avenue, New York, NY 10021, United States.
E-mail: dunkeli@mskcc.org

SO Cancer, (15 NOV 2000), 89/10 (2117-2121), 17 reference(s)

CODEN: CANCAR ISSN: 0008-543X

DT Journal; Article

CY United States

LA English

SL English

L3 ANSWER 67 OF 76 US PATFULL on STN

AN 1999:53572 US PATFULL

TI Correction of genetic defects using chemical chaperones

IN Welch, William J., 48 Fountain, San Francisco, CA, United States 94114
Brown, C. Randell, 1470 9th Ave. #12, San Francisco, CA, United States
94122

Tatzelt, Jorg, 740 Parnassus, San Francisco, CA, United States 94122

PI US 5900360 19990504

AI US 1997-838691 19970409 (8)

PRAI US 1996-15155P 19960410 (60)

DT Utility

FS Granted

LN.CNT 2062

INCL INCLM: 435/029.000

INCLS: 435/004.000; 435/005.000; 435/034.000; 436/063.000; 436/086.000;
436/506.000; 436/811.000

NCL NCLM: 435/029.000

NCLS: 435/004.000; 435/005.000; 435/034.000; 436/063.000; 436/086.000;
436/506.000; 436/811.000

IC [6]

ICM: C12Q001-02

ICS: C12Q001-04; G01N033-48; G01N033-564

EXF 435/29; 435/34; 435/4; 435/5; 436/86; 436/63; 436/811; 436/506

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 68 OF 76 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN DUPLICATE
12

AN 1998-11346 DRUGU T S

TI Much ado about not... enough data: high-dose chemotherapy with autologous
stem cell rescue for breast cancer.

AU Zujewski J; Nelson A; Abrams J

LO Bethesda; Potomac, Md., USA
SO J.Natl.Cancer Inst. (90, No. 3, 200-91, 1998) 1 Fig. 8 Tab. 51 Ref.
CODEN: JNCIEQ ISSN: 0027-8874
AV National Institutes of Health, Bldg. 10 Rm. 12N/226, Bethesda, MD 20892,
U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 69 OF 76 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS RESERVED.
on STN
AN 1996-0380308 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN High dose consolidation with autologous stem cell rescue (***ASCR***)
for nephroblastoma initially treated according to the SIOP 9/GPOH trial
and study
AU HEMPEL L.; KREMENS B.; WEIRICH A.; GRAF N.; ZINTL F.; LUDWIG R.
CS Dept. of Pediatric Hematology and Oncology, University of Jena, Germany,
Federal Republic of
SO Klinische Paediatric, (1996), 208(4), 186-189, 18 refs.
ISSN: 0300-8630 CODEN: KLPDB2
DT Journal
BL Analytic
CY Germany, Federal Republic of
LA English
SL German
AV INIST-4105, 354000060429320080

L3 ANSWER 70 OF 76 CANCERLIT on STN
AN 96604645 CANCERLIT
DN 96604645
TI High-dose chemotherapy with bone marrow transplantation in the treatment
of breast cancer (Meeting abstract).
AU Fields K K; Elfenbein G J
CS Div. of Bone Marrow Transplantation, Univ. of South Florida, Tampa, FL
33612.
SO Cancer Invest, (1995) 13 (Suppl 1) 12-3.
ISSN: 0735-7907.
DT (MEETING ABSTRACTS)
LA English
FS Institute for Cell and Developmental Biology
EM 199605
ED Entered STN: 19970509
Last Updated on STN: 19970509

L3 ANSWER 71 OF 76 CABA COPYRIGHT 2004 CABI on STN DUPLICATE 13
AN 96:29330 CABA
DN 19960101143
TI Ablation of the prion protein (PrP) gene in mice prevents scrapie and
facilitates production of anti-PrP antibodies
AU Prusiner, S. B.; Groth, D.; Serban, A.; Koehler, R.; Foster, D.; Torchia,
M.; Burton, D.; Yang ShuLian; DeArmond, S. J.; Yang, S. L.
CS Department of Neurology, University of California, San Francisco, CA
94143, USA.
SO Proceedings of the National Academy of Sciences of the United States of
America, (1993) Vol. 90, No. 22, pp. 10608-10612. 53 ref.
ISSN: 0027-8424
DT Journal
LA English
ED Entered STN: 19960318
Last Updated on STN: 19960318

L3 ANSWER 72 OF 76 CANCERLIT on STN
AN 95606623 CANCERLIT
DN 95606623
TI High dose mitoxantrone (M) thiotepa (T) and cyclophosphamide (C) plus
autologous stem cell rescue (***ASCR***) in patients with breast
cancer (Meeting abstract).
AU Taylor C W; List A F; Azar C A; Rifkin R M; Mosley K; Dalton W S
CS Arizona Cancer Center, Tucson AZ 85724.
SO Breast Cancer Treat Res, (1993) 27 (1/2) 183.
ISSN: 0167-6806.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology

EM 199503
ED Entered STN: 19950313
Last Updated on STN: 19950313

L3 ANSWER 73 OF 76 CANCERLIT on STN DUPLICATE 14
AN 94073488 CANCERLIT
DN 94073488 PubMed ID: 7902764
TI Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.
AU Fields K K; Perkins J P; Hiemenz J W; Zorsky P E; Janssen W E; Kronish L E; Machak M C; Elfenbein G J
CS Department of Internal Medicine, H. Lee Moffitt Cancer Center, University of South Florida, Tampa 33612.
SO SURGICAL ONCOLOGY, (1993) 2 (1) 87-95.
Journal code: 9208188. ISSN: 0960-7404.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 94073488
EM 199401
ED Entered STN: 19941107
Last Updated on STN: 19950508

L3 ANSWER 74 OF 76 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1992-26777 DRUGU T S
TI Ifosfamide, Carboplatin and Etoposide (ICE) with Autologous Stem Cell Rescue (***ASCR***): Toxicities.
AU Elfenbein G; Fields K; Zorsky P; Hiemenz J; Janssen W; Perkins J
LO Tampa, Florida, United States
SO Proc.Am.Soc.Clin.Oncol. (11, 28 Meet., 90, 1992)
AV Div. Bone Marrow Transplant, Univ. of South Fla., Tampa, FL, U.S.A. (11 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 75 OF 76 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 15
AN 1990:91415 BIOSIS
DN PREV199089050766; BA89:50766
TI HIGH-DOSE CONSOLIDATION THERAPY WITH AUTOLOGOUS STEM CELL RESCUE IN STAGE IV BREAST CANCER.
AU WILLIAMS S F [Reprint author]; MICK R; DESSER R; GOLICK J; BESCHORNER J; BITRAN J D
CS UNIV CHICAGO, BOX 420, 5841 S MARYLAND AVE, CHICAGO, ILL 60637, USA
SO Journal of Clinical Oncology, (1989) Vol. 7, No. 12, pp. 1824-1830.
CODEN: JCONDN. ISSN: 0732-183X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 Feb 1990
Last Updated on STN: 9 Feb 1990

L3 ANSWER 76 OF 76 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1990-16751 DRUGU T S
TI A Phase II Study of Induction Chemotherapy Followed by Intensification with High Dose Chemotherapy with Autologous Stem Cell Rescue (***ASCR***) in Stage IV Breast Cancer.
AU Williams S; Bitran J; Desser R; Golick J; Beschorner J; Fullem L
LO Chicago, Illinois, United States
SO Proc.Am.Soc.Clin.Oncol. (7, 24 Meet., 9, 1988)
AV Joint Section of Hematology/Oncology, University of Chicago and Michael Reese Medical Centers, Chicago, IL 60637, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature
STN INTERNATIONAL LOGOFF AT 17:07:16 ON 09 SEP 2004